Archive Course Catalog


Browse archived online courses and resources.

ACI 22-23 Online Interactive Courses
Collapse Advances in Cancer Immunotherapy™: Toxicity Management

Published 12/21/2022

 

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

 

This interactive course, Toxicity Management provides information on incidence, onset, severity, and grading of immune-related toxicities and irAEs with immune checkpoint inhibitors. Dr. Alexa Meara and Dr. Pankti Reid have also presented cases focussing irAEs, treatment plan, and management. 

 

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

  PIM_logo.pngsitc_log_color.png

 

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

 

Credit Available: December 21, 2022 - December 21, 2023

 

Estimated time to complete activity: 90 minutes

 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

 

Learning Objectives

At the end of this activity, the participant should be able to:

  • Identify immune-related toxicities by grade, onset, and incidence.
  • Identify immune-related adverse events resulting from immune checkpoint inhibitors.
  • Describe the adverse events and management of cellular therapies.
  • Describe the precautions needed when immunotherapy is provided to special patient populations.

 

Faculty

Alexa S. Meara, MD

Associate Professor

Division of Oncology

Division Rheumatology and Immunology

The Ohio State Wexner Medical Center, Ohio

 

Pankti Reid, MD, MPH

Assistant Professor

University of Chicago Medical Center, Illinois

Department of Medicine- Division of Rheumatology

Committee on Clinical Pharmacology and Pharmacogenomics

 

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 
 

Alexa Meara, MD - Consultant/Advisor/Speaker:  Abbvie, GSK, Amgen, Sanofi, Aurinia

 

Pankti Reid, MD - Royalty and Patent Beneficiary: Patent pending for use of interleukin 6 axis inhibitor for viral infection associated pneumonitis  

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

 

Method of Participation and Request for Credit

During the period 12/21/2022 through 12/21/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

 

Joint Accreditation Statement

Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

 

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of  1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CME-MOC_badge.jpg

 

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hour. Designated for 1 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

 

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour (1.5 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-494-H01-P

Type of Activity: Knowledge


Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

Original Course Date: December 21, 2022

Approved Credit:
  • ACPE: 1.50 hours Contact Hour
  • ANCC: 1.50 hours Contact Hour
  • : 1.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: Toxicity Management
    Collapse Advances in Cancer Immunotherapy™: A Focus on Immune Checkpoint Inhibitors

    This course is no longer available for credit.

    Published 5/20/2022

     

    Course Description

    This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Immune Checkpoint Inhibitors. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    Funders Statement

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: May 20, 2022 - May 20, 2023

     

    Estimated time to complete activity: 3.75 hours

     

    Faculty: 

    Marina Chiara Garassino, MD - The University of Chicago

    Natalie Vokes, MD - The University of Texas MD Anderson Cancer Center

    Jarushka Naidoo, MBBCH, MHS - Beaumont RCSI Cancer Centre, Dublin

    Diane Tseng, MD, PhD - University of Washington School of Medicine, Fred Hutchinson Cancer Research Center

    Bonnie Bermas, MD - UT Southwestern Medical Center

    Vickie Shannon, MD - The University of Texas MD Anderson Cancer Center

    Sadia Ali, MD - UT Southwestern Medical Center

    Nikhil I. Khushalani, MD - Moffitt Cancer Center

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the mechanisms of immune checkpoint inhibitors.
    • Summarize recent updates in the use of immune checkpoint inhibitors clinically.
    • Outline common toxicities with immune checkpoint inhibitors and their management.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.25 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-240-H01-P)

    Type of Activity: Knowledge

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

     


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Original Course Date: April 23, 2022

    Approved Credit:
  • ACPE: 3.75 hours Contact Hour
  • ANCC: 3.75 hours Contact Hour
  • ACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on Immune Checkpoint Inhibitors
    Collapse Advances in Cancer Immunotherapy™: Mechanisms of Immune-Related Adverse Events

    This course is no longer available for credit.

     

    Published May 23, 2022

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This interactive course provides an overview of the mechanisms of immune-related adverse events (irAEs) that may be caused by implementing cancer immunotherapy.  This module walks the learner through the various mechanisms of irAEs, as well as differentiating early and late irAEs which may be distinguished by distinct mechanisms.  Learners will also have the opportunity to apply the knowledge gained in this module through two case studies.  

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: May 23, 2022 - May 23, 2023

     

    Estimated time to complete activity: 15 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify the various mechanisms of irAEs as well as the types of irAEs that may result.
    • Describe various irAEs as well as treatment for severe irAEs.
    • Differentiate central vs. peripheral tolerance of irAEs.

     

    Faculty
    Pradnya Patil, MD, FACP

    Associate Staff / Department of Hematology-Oncology

    Cleveland Clinic, Cleveland

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Pradnya Patil, MD, FACP - Nothing to disclose.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period May 23, 2022 through May 23, 2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of  0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. 

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-279-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: March 16, 2022

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: Mechanisms of Immune-Related Adverse Events
    Collapse Advances in Cancer Immunotherapy™: A Focus on Skin Cancers

    This course is no longer available for credit.

    Published 3/24/2022

     

    Course Description

    This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Skin Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    Funders Statement

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: March 24, 2022 - March 24, 2023

     

    Estimated time to complete activity: 3.75 hours

     

    Faculty:

    Allison Betof Warner, MD, PhD - Memoral Sloan Kettering Cancer Center

    Isabella C. Glitza, MD, PhD - The University of Texas MD Anderson Cancer Center

    Janice Mehnert, MD - NYU Langone Health

    Michael K. Wong - MD, PhD - The University of Texas MD Anderson Cancer Center

    Ryan J. Sullivan, MD - Harvard Medical School, Massachusetts General Hospital

    Omid Hamid, MD - The Angeles Clinic and Research Institute

    Jarushka Naidoo, MBBCH, MHS - Beaumont RCSI Cancer Centre Dublin

    Kathy Madden, NP, RN, MSN, FNP-BC, AOCNP, APHN - NYU Langone Perlmutter Cancer Center

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify the cancer immunotherapy approaches in use for the treatment of skin cancers.
    • Summarize recent updates in cancer immunotherapy for skin cancers, including emerging toxicities and managment.
    • Implement cancer immunotherapy for skin cancer into clinical pratice appropriately.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number  - JA4008162-9999-22-130-H01-P

    Type of Activity: Knowledge

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: February 24, 2022

    Approved Credit:
  • ACPE: 3.75 hours Contact Hour
  • ANCC: 3.75 hours Contact Hour
  • ACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on Skin Cancers
    Collapse Advances in Cancer Immunotherapy™: A Focus on Intratumoral Therapies, Vaccines, and Cytokines

    This course is no longer available for credit.

    Published 2/24/2022

     

    Course Description

    This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Intratumoral Therapies, Vaccines, and Cytokines. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    Funders Statement

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: February 24, 2022 - February 24, 2023

     

    Estimated time to complete activity: 3.75 hours

     

    Faculty: 

    Diwakar Davar, MMBBS, MSc - UPMC Hillman Cancer Center

    Patrick Ott, MD, PhD - Dana Farber Cancer Institute

    Adi Diab, MD - The University of Texas MD Anderson Cancer Center

    Harriet Kluger, MD - Yale School of Medicine

    Matthew J. Frigault, MD, MSc - Massachusetts General Hospital

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the mechanisms of intratumoral therapies, vaccines, and cytokines.
    • Summarize recent updates in the use of intratumoral therapies, vaccines, and cytokines clinically.
    • Outline common toxicities with intratumoral therapies, vaccines, and cytokines, and their management.

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.6 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-073-H01-P)

    Type of Activity: Knowledge

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: January 27, 2022

    Approved Credit:
  • ACPE: 3.75 hours Contact Hour
  • ANCC: 3.75 hours Contact Hour
  • ACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on Intratumoral Therapies, Vaccines, and Cytokines
    Collapse Advances in Cancer Immunotherapy™: A Focus on Head and Neck Cancers

    This course is no longer available for credit.

    Published 2/9/2022

     

    Course Description

    This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Head and Neck Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    Funders Statement

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: February 9, 2022 - February 9, 2023

     

    Estimated time to complete activity: 3.75 hours

     

    Faculty: 

    Jessica R. Bauman, MD - Fox Chase Cancer Center

    Jessica L. Geiger, MD - Cleveland Clinic Cancer Center

    Dan P. Zandberg, MD - UPMC Hillman Cancer Center

    Tanguy Seiwert, MD - Johns Hopkins Medicine

    Trisha Wise-Draper, MD, PhD - University of Cincinnati Cancer Center

    Ranee Mehra, MD - University of Maryland

    Ravindra Uppaluri, MD, PhD - Dana Farber Cancer Institute and Brigham and Women's Hospital

    Sana Karam, MD, PhD - University of Colorado

    Aarti Bhatia, MD - Yale School of Medicine

    Sid Sheth, MD - UNC School of Medicine

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify the cancer immunotherapy approaches in the use for the treatment of head and neck cancers.
    • Summarize recent updates in cancer immunotherapy for head and neck cancers as well as toxicity management for key disease states.
    • Implement cancer immunotherapy for head and neck cancers into clinical practice appropriately.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.6 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-052-H01-P)

    Type of Activity: Knowledge

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Original Course Date: January 12, 2022

    Approved Credit:
  • ACPE: 3.75 hours Contact Hour
  • ANCC: 3.75 hours Contact Hour
  • ACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on Head and Neck Cancers
    2023 CE Courses
    Collapse 2023 Advances in Cancer Immunotherapy™: Patient education (Outpatient Cell therapies/T Cell Engagers)

    Published: On Date

     

    Please note, this activity does not offer continuing education credit.

    The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Additional support for this activity provided by:

     

    Course Description and Target Audience
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, advanced practitioners, emergency physicians and all members of the cancer team, the ACI program focuses on how to educate your patients about receiving inpatient/outpatient cellular therapies; including examples of practical implementation provided


    Estimated time to complete activity: 25 Minutes

    Learning Objectives
    At the conclusion of this activity, the participant should be able to:

    • Understand the patient journey and how to prepare a patient for these steps.

    • To be informed of the many time points that require patient education and reinforcement.

    • Develop an understanding about the varying pieces of education necessary for patient success.

    • How to properly prepare patients and their caregivers for outpatient CAR-T cell therapy.

     

    Satisfactory Completion
    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

     

    Faculty and Disclosure of Conflicts of Interest

    No relevant financial conflicts.

    Faculty
    Meaghan Ekstrom, BA, BSN, MSN, FNP-BC
    Massachusetts General Hospital
    Boston, MA

    The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

    SITC Online Education Disclaimer
    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Original Course Date: December 25, 2023

    Approved Credit:
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Patient education (Outpatient Cell therapies/T Cell Engagers)
    Collapse 2023 Advances in Cancer Immunotherapy™: Difficult-to-treat Cases

    Published Date: 12/01/2023

    Expiration Date: 12/01/2024

     

    Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

    The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. In the course Difficult-to-treat Cases, Subject Matter Expert- David A. Braun, MD, PhD of Yale School of Medicine has endorsed the effectiveness of Immunotherapy in treating patients with Renal Cell Carcinoma. There are 3 real life difficult to treat case scenarios that elaborate tests, treatment plans, and the outcomes. The Subject Matter Expert reinforced his treatment plans while sharing the risk factors involved using the results of various clinical trials.

     

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete the activity: 45 minutes

    For additional information about the accreditation of this activity, please visit https://partnersed.com

     

    Hardware and Software Requirements
    SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

                                                                                                                               

    Educational Objectives:                                                  

    Upon completion of this activity, participants should be able to:

    • Identify the benefits and risks of adjuvant immune checkpoint inhibitor (ICI) therapy with help of case studies.
    • Recognize the differences between front-line ICI-based therapies for metastatic disease.
    • Explain the treatment options for “PD-1—refractory” disease.

     

    Faculty and Disclosure of Conflicts of Interest

    PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

     

    Faculty:

    David A. Braun, MD, PhD       

    Assistant Professor, Goodman and Gilman Yale Scholar- Yale Cancer Center, Yale School of Medicine

     

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

     

    Conflicts of Interest:
    Consultant/Advisor/Speaker: Exelixis, AVEO, Charles River Associates, Schlesinger Associates, Imprint Science, Insight Strategy, Trinity Group, Cancer Expert Now, Adnovate Strategies, MDedge, CancerNetwork, Catenion, OncLive, Cello Health BioConsulting, PWW Consulting, Haymarket Medical Network, Aptitude Health, ASCO Post/Harborside, Targeted Oncology, AbbVie.

    The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Education

    PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    American Board of Internal Medicine Maintenance of Certification

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    Nursing Continuing Professional Development

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

     

    Pharmacy Continuing Education

    PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008073-9999-23-305-H01-P)

    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Instructions for Credit

    During the period 12/01/2023 through 12/01/2024, participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 75% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

     

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


     

    Original Course Date: December 01, 2023

    Approved Credit:
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Difficult-to-treat Cases
    Collapse 2023 Advances in Cancer Immunotherapy™: irAEs associated with Cellular Therapies and T-cell Engagers

    Published: On 10/05/2023

     

    Please note, this activity does not offer continuing education credit.

    The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Additional support for this activity provided by:

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

     

    The course irAES associated with Cellular Therapies and T-cell Engagers starts with an overview of cellular therapies and bisepcific antibodies. Dr. Loretta Nastoupil of UT MD Anderson Cancer Center has described the immune related acute and late adverse events associated with CAR T-cell therapies and potential approches to management of toxicities. The case studies presented by Dr. Nastoupil help decide the best possible action plan for managing toxicities associated with CAR T-cell therapies in patients.


    Estimated time to complete activity:  40 Minutes

     

    Target Audience
    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives
    At the conclusion of this activity, the participant should be able to:

    • Give a brief overview of the mechanism of action and common toxicities associated with cellular therapies and T cell engagers.

    • List the multiple approaches that should be followed post treatment.

    • Describe the immune related acute and late adverse events (toxicities) associated with CAR-T cell therapies.

    • Describe similar acute toxicities associated with T-cell engagers and potential different approaches to management.

    • Explain the action plan for the management of toxicities associated with CAR-T cell therapies.

     

    Satisfactory Completion
    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

     

    Faculty and Disclosure of Conflicts of Interest

     

    Faculty
    Loretta Nastoupil, MD
    Associate Professor
    UT MD Anderson Cancer Center
    Texas, USA

     

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

     

    Conflicts of Interest
    Researcher: BMS, Caribou Biosciences, Daiichi Sankyo, Epizyme, Genentech, Gilead/Kite, IGM Biosciences, Janssen, Novartis, Takeda
    Consultant/ Advisor/ Speaker: Abbvie, Atara, BMS, Caribou Biosciences, Daiichi Sankyo, Epizyme, Genentech, Gilead/Kite, Janssen, Merck, Novartis, Takeda


    The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

     

    SITC Online Education Disclaimer
    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Original Course Date: October 06, 2023

    Approved Credit:
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: irAEs associated with Cellular Therapies and T-cell Engagers
    Collapse 2023 Advances in Cancer Immunotherapy™: Combination Therapies in Combating Cancer

    Published: On 08/11/2023

     

    Please note, this activity does not offer continuing education credit.

    The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

    Additional support for this activity provided by:

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

     

    The course- Combination therapies in Combating Cancer gives a brief overview of the several combination therapies such as Inhibitory Immune Checkpoint Combination therapy, Targeted Immunotherapy approches, and other emerging combination therapies. In this course, the subject matter expert describes the effectiveness of various combination immunotherpy approches and their outcomes in cancer patients using several case studies and research papers. The course content emphasizes the emerging landscape of combining immunotherapy with different modalities to treat cancer. 

     

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete activity:  1 hour

     

    Target Audience
    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives
    At the conclusion of this activity, the participant should be able to:

    • Describe key immunotherapy targets that are useful for combination approaches.
    • Describe immunotherapy-based combination treatment regimens currently under investigation.
    • Discuss the emerging landscape of combining immunotherapy with different modalities to treat cancer.

     

    Satisfactory Completion
    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

     

    Faculty
    Gregory B. Lesinski, PhD, MPH
    Co-Director, Translational GI Malignancy Program
    Winship Cancer Institute of Emory University,
    Atlanta, Georgia, USA

     

    Disclosure of Conflicts of Interest
    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 
    Gregory B. Lesinski, PhD, MPH: Works at a Academic Medical Center and a consultant advisor speaker for Bristol-Myers Squib, Vaccinex, Boerhinger-Ingelheim, Merck and Co.

    The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

     

    SITC Online Education Disclaimer
    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     

    Original Course Date: August 11, 2023

    Approved Credit:
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Combination Therapies in Combating Cancer
    Collapse 2023 Advances in Cancer Immunotherapy™: Introduction to Biomarkers

    Published Date: 06/30/2023

    Expiration Date: 06/30/2024

     

    Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

    The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. The course, Introduction to Biomarkers provides an overview on types of biomarkers and its significance in treatment of cancer. The SME has discussed various findings and outcomes of the clinical trial initiatives related to biomarkers.

     

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete the activity: 45 minutes

    For additional information about the accreditation of this activity, please visit https://partnersed.com

     

    Hardware and Software Requirements
    SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

                                                                                                                               

    Educational Objectives:                                                  

    Upon completion of this activity, participants should be able to:

    • Define the term biomarker.
    • Explain the functions of biomarkers.
    • Differentiate the biomarkers based on their types.
    • Describe the use of biomarkers in various cancer treatments.
    • Summarize the challenges of using biomarkers in the treatment of cancer.

     

    Faculty and Disclosure of Conflicts of Interest

    PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

     

    Faculty:

    Dr. Paolo A. Ascierto, MD
    Director of Department of Melanoma
    UOC Melanoma, Immunoterapia Oncologica e Terapie Innovative
    Istituto Nazionale Tumori – Fondazione “G. Pascale”
    Napoli, Italy

     

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

     

    Conflicts of Interest:
    Researcher: Bristol Myers Squibb, Roche-Genentech, Pfizer, Sanofi
    Consultant/Advisor/Speaker: Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTX, Replimmune, Bayer

    The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Education

    PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    American Board of Internal Medicine Maintenance of Certification

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    Nursing Continuing Professional Development

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

     

    Pharmacy Continuing Education

    PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008073-9999-23-162-H01-P)

    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Instructions for Credit

    During the period 06/30/2023 through 06/30/2024, participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

     

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


     

    Original Course Date: June 30, 2023
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Introduction to Biomarkers
    Collapse 2023 Advances in Cancer Immunotherapy™: Mechanisms of Immune-related Adverse Events (irAEs)

    Published Date: 06/01/2023

    Expiration Date: 06/01/2024

     

    Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

    The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. The course, Mechanisms of Immune-related Adverse Events (irAEs) provides an insight into the host factors that increase the risk of irAEs. The course briefly explains the differences in toxicities of CTLA-4 and PD-1 immune checkpoint inhibitors. The two case studies presented in course enables the learners to assess the immune-related response of immunotherapy treatment in a patient.

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete the activity: 45 minutes

    For additional information about the accreditation of this activity, please visit https://partnersed.com

     

    Hardware and Software Requirements
    SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

                                                                                                                               

    Educational Objectives:                                                  

    Upon completion of this activity, participants should be able to:

    • Explain the Mechanisms of immune related Adverse Events in brief.
    • Describe the other host factors that affect the risk of immune related Adverse Events.
    • Summarize the differences in PD-L1 and CTLA-4 toxicities.
    • Explain the response assessment process in a patient for the immunotherapy treatment.

     

    Faculty and Disclosure of Conflicts of Interest

    PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    Faculty:

    Pradnya Patil, MD, FACP
    Associate Staff Oncologist
    Taussig Cancer Center, Cleveland Clinic
    Cleveland, OH

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

    Conflicts of Interest:
    Consultant/Advisor/Speaker: AstraZeneca, Jazz Pharmaceuticals

     

    The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Education

    PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    American Board of Internal Medicine Maintenance of Certification

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    Nursing Continuing Professional Development

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

     

    Pharmacy Continuing Education

    PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008073-9999-23-151-H01-P)

    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Instructions for Credit

    During the period 06/01/2023 through 06/01/2024 participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

     

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Original Course Date: May 30, 2023
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Mechanisms of Immune-related Adverse Events (irAEs)
    Collapse 2023 Advances in Cancer Immunotherapy™: Introduction to Immunology

    Published Date: 05/05/2023

    Expiration Date: 05/05/2024

     

     

    Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

    The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team. The ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

    This course, Introduction to Immunology provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy.

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete the activity: 1 hour

    For additional information about the accreditation of this activity, please visit https://partnersed.com

     

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

                                                                                                                               

    Educational Objectives:                                                  

    Upon completion of this activity, participants should be able to:

    • Describe the function of the components of the immune system, including relevant cells, molecules, and organs of the immune system.
    • Differentiate between the adaptive immune system and the innate immune system.
    • Recognize the barriers to effective immunotherapy, including mechanism by which tumors locally disable and/or evade the immune system.

     

    Faculty and Disclosure of Conflicts of Interest

    PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    Faculty:

    Chrystal M. Paulos, PhD
    Director of Translational Research, Cutaneous Malignancies
    Winship Cancer Institute at Emory University

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

    Conflicts of Interest:
    IP Rights: Ares Immunotherapy
    Consulting Fees: Ares Immunotherapy
    Founder/Owner: Ares Immunotherapy
    Other (subcontracts): Obsidian, Lycera, ThermaFisher

     

    The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

     

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Education

    PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    American Board of Internal Medicine Maintenance of Certification

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    Nursing Continuing Professional Development

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses. 

     

    Pharmacy Continuing Education

    PACE designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008073-9999-23-142-H01-P)

    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Instructions for Credit

    During the period 05/05/2023 through 05/05/2024 participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

     

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Original Course Date: May 05, 2023
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 1 hour Contact Hour
  • ANCC: 1 hour Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Introduction to Immunology
    Collapse 2023 Advances in Cancer Immunotherapy™: Basic Principles of Cancer Immunotherapy

    Published: On 04/28/2023

    Please note, this activity does not offer continuing education credit.

    The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

    Additional support for this activity provided by:

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

    This course, Basic Principles of Cancer Immunotherapy will walk the learner through the biological foundations of immunotherapy, types of immunotherapies, illustrate how biomarkers play a major role in immunotherapy, as well as cover the patient response to immunotherapy and subsequent physician assessment.  

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete activity:  1 hour

     

    Target Audience
    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives
    At the conclusion of this activity, the participant should be able to:

    • Describe the concept of Immunotherapy.
    • Identify the various types of cancer immunotherapy.
    • Describe the rationale for common approaches to cancer immunotherapy.
    • Explain the response assessment process in a patient for the immunotherapy treatment.

     

     

    Satisfactory Completion
    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

     

     

    Faculty
    Christian M. Capitini, MD
    Associate Professor
    University of Wisconsin-Madison

    Disclosure of Conflicts of Interest
    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 
    Christian M. Capitini, MD: Works at a Academic Medical Center and a consultant advisor speaker for Bayer, Elephas, Novartis, Nektar Therapeutics, WiCell Research Institute

    The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

     

    SITC Online Education Disclaimer
    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


     

     

    Original Course Date: April 28, 2023

    Approved Credit:
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Basic Principles of Cancer Immunotherapy
    2022 Courses
    Collapse Evaluating the Role of Immunotherapy in Urothelial Carcinoma: How Do We Make the Right Choices?

    Join Thomas Powles, MBBS, MRCP, MD, Andrea Necchi, MD, and Cora N. Sternberg, MD, FACP in a discussion on the role of immunotherapy in urotherlial carcinoma.


    This educational activity is intended for an international audience of non-US hematologists/oncologists and urologists. The goal of this activity is to increase oncologists' and urologists' understanding of the role of immunotherapy in the treatment of locally advanced or metastatic urothelial carcinoma.
     


    Learning Objectives:

    Upon completion of this activity, participants will:

    • Have increased knowledge regarding the
      • Available immunotherapy strategies for locally advanced/metastatic urothelial carcinoma
      • Supporting evidence for immunotherapy strategies for locally advanced/metastatic urothelial carcinoma
    • Have greater competence related to
      • Selecting the right immunotherapy strategy for the right patient with locally advanced/metastatic urothelial carcinoma

    Approximate Time to Complete: 30 minutes

    Credit Available: March 11, 2022 - March 11, 2023

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Resources for Clinicans from SITC:

     

     

    Original Course Date: March 18, 2022

    Approved Credit:
  • CoP: 0.50 hours Certificate of Participation

  • MORE INFOMORE INFO Evaluating the Role of Immunotherapy in Urothelial Carcinoma: How Do We Make the Right Choices?
    Collapse Exploring the Role of Immunotherapy in Advanced Non-Small Cell Lung Cancer Without Targetable Mutations

    Exploring the Role of Immunotherapy in Advanced Non-Small Cell Lung Cancer Without Targetable Mutations

    Join Hossein Borghaei, DO, MS, Ramaswamy Govindan, MD, Charu Aggarwal, MD, MPH, and Jarushka Naidoo, MBBCh in a discussion on the role of immunotherapy in advanced non-small cell lung cancer without targetable mutations.

    This activity is intended for hematologists/oncologists, pulmonologists, and pathologists.

    The goal of this activity is that learners will have an increased awareness of immunotherapeutic regimens as first-line treatment for NSCLC and be better able to identify and manage immune-related adverse events using a multidisciplinary approach.
     


    Learning Objectives:

    • Have increased knowledge regarding the
      • Rationale for using immunotherapy in early-stage NSCLC
      • Key clinical trial data evaluating immunotherapy in the treatment of early-stage NSCLC
    • Demonstrate greater confidence in their ability to
      • Understanding of the latest data on immunotherapy in the treatment of early-stage NSCLC

    Approximate Time to Complete: 30 minutes

     

    Credit Available: March 11, 2022 - March 11, 2023

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Resources for Clinicans from SITC:

     

     

    Original Course Date: March 18, 2022

    Approved Credit:
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 0.50 hours CEU
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO Exploring the Role of Immunotherapy in Advanced Non-Small Cell Lung Cancer Without Targetable Mutations
    Collapse Immunotherapy in Early-Stage NSCLC

    Immunotherapy in Early-Stage NSCLC

    Dr Borghaei and Dr Chaft join to discuss recent clinical data supporting the use of immunotherapy in early-stage NSCLC.

     

    The goal of this activity is to provide insight on the rationale and clinical trial data for immunotherapy in the treatment of patients with early-stage non-small cell lung cancer (NSCLC).

     

    This activity is intended for oncologists, pulmonologists, and pathologists.

     

     

     

    Learning Objectives:

    • Have increased knowledge regarding the
      • Rationale for using immunotherapy in early-stage NSCLC
      • Key clinical trial data evaluating immunotherapy in the treatment of early-stage NSCLC
    • Demonstrate greater confidence in their ability to
      • Understanding of the latest data on immunotherapy in the treatment of early-stage NSCLC

    Approximate Time to Complete: 30 minutes

     

    Credit Available: February 25, 2022 - February 25, 2023

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

     

    Additional Resources for Clinicans from SITC:

     

     

    Original Course Date: February 25, 2022

    Approved Credit:
  • ACCME (MD/DO): 0.25 hours AMA PRA Category 1 Credit(s)™
  • : 0.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy in Early-Stage NSCLC
    Collapse Optimizing the Management of Squamous Cell Carcinoma of the Head and Neck With Immunotherapeutic Strategies

    Optimizing the Management of Squamous Cell Carcinoma of the Head and Neck With Immunotherapeutic Strategies

    Drs Weiss and Burtness discuss the latest immunotherapeutic strategies in the management of head and neck cancers.

     

    The goal of this initiative is to update clinicians about the evidence base on cancer immunotherapies, including the role of biomarkers, and provide guidance on applying these data to improve performance and increase confidence in integrating immunotherapeutic regimens into practice.

     

    This activity is intended for oncologists, otolaryngologists, and pathologists on the SCCHN care team.

     

     

     

    Learning Objectives:

    • Have increased knowledge regarding the
      • Current treatment paradigm for metastatic SCCHN
      • Key clinical trial data evaluating immune-modulating therapies for the treatment of SCCH
    • Demonstrate greater confidence in their ability to
      • Integrate key clinical trial data into practice for the treatment of patients with SCCHN 

    Approximate Time to Complete: 30 minutes

     

    Credit Available: February 24, 2022 - February 24, 2023

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

     

    Additional Resources for Clinicans from SITC:

     

     

    Original Course Date: February 24, 2022

    Approved Credit:
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Optimizing the Management of Squamous Cell Carcinoma of the Head and Neck With Immunotherapeutic Strategies
    2021 Courses
    Collapse Immunotherapy for the Treatment of Microsatellite Instability or Tumor Mutation Burden - High Cancers

    This course is no longer available for credit.

    Published 10/07/2021

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Microsatellite Instability or Tumor Mutational Burden-High Cancers, provides an overview of immunotherapy treatment for cancers with these characteristics. This course will help the learner understand what microsatellite instability (MSI)  and tumor mutational burden (TMB) terms mean, what meaures can be performed to identify MSI/TMB, various FDA-approved regimens for cancers that are MSI/TMB-high, and provide current clinical trial information.    Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy for the treatment of cancers with high or low microsatellite instability and/or tumor mutational burden.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available: October 7, 2021 - October 7, 2022

     

    Estimated time to complete activity: 30 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Define the meaning of microsatellite instability and tumor mutational burden.
    • Identify the methods used to measure MSI or TMB.
    • Describe the rationale for common approaches to cancer immunotherapy with MSI/TMB measures identified.

     

    Faculty
    Dung Le, MD

    Associate Professor, GI Medical Oncology

    Sydney Kimmel Cancer Care Center, Johns Hopkins University

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Dung Le, MD: Consulting Fees: Merck, Bristol Myers Squibb, Janssen, Nouscom.   Contracted Research: Merck, Bristol Myers Squibb, Aduro Biotech, Medivir, Curegenix, Nouscom

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 10/7/2021 through 10/7/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-3027-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Microsatellite Instability or Tumor Mutation Burden - High Cancers
    Collapse Immunotherapy for the Treatment of the Head and Neck Cancer

    Published 3/15/2022

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program.  Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Head and Neck Cancer, provides an overview of immunotherapy treatment for head and neck cancers. Multiple clinical trials dealing with head and neck cancers are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for head and neck cancers.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  March 15, 2022 - March 15, 2023

     

    Estimated time to complete activity:  30 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Implement cancer immunotherapy treatment for head and neck cancer.
    • Identify immune-related toxicities related to head and neck cancer immunotherapy agents, and also used in combination with chemotherapy agents.
    • Describe the rationale for common approaches to cancer immunotherapy.

     

    Faculty
    Anshu Giri, MD, MS

    Assistant Professor, Department of Hematology/Oncology

    Fox Chase Cancer Center

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Anshu Giri, MD, MS: Nothing to disclose. 

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 3/15/2022 through 03/15/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.4 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-109-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of the Head and Neck Cancer
    Collapse Immunotherapy for the Treatment of Gastrointestinal Cancers

    This course is no longer available for credit.

    Published: 3/1/2022

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Gastrointestinal Cancers, provides an overview of immunotherapy treatment for hepatocellular, colorectal, and other gastrointestinal malignancies. Multiple clinical trials dealing with these types of cancer are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for gastrointestinal cancers.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  March 1, 2022 - March 1, 2023

    Estimated time to complete activity:  30 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Implement cancer immunotherapy treatment for gastrointestinal cancer.
    • Identify various studies that are stil ongoing as well as completed clinical trials which have resulted in approvals by disease state.
    • Describe the rationale for common approaches to cancer immunotherapy.

     

    Faculty
    Aiwu Ruth He, MD, PhD

    Associate Professor of Medicine, Medstar Georgetown University Hospital

    Georgetown University

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Aiwu Ruth He, MD, PhD:  Consulting Fees: Merck, Bayer, BMS, Aztrazeneca; Fees for Non-CE Service: Eisai, BMS, Exelixis; Contracted Research: Merck, Genentech

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 3/1/2022 through 03/01/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number  - JA4008162-9999-22-082-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Gastrointestinal Cancers
    Collapse Immunotherapy for the Treatment of Genitourinary Malignancies

    This course is no longer available for credit.

    Published 11/1/2021

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Genitourinary Malignancies, provides an overview of immunotherapy treatment for renal cell carcinoma, urothelial carcinoma, and prostate cancer. Multiple clinical trials dealing with all three cancer types are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for these cancers.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available: November 1, 2021 - November 1, 2022

     

    Estimated time to complete activity:  30 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Implement cancer immunotherapy treatment for renal cell carcinoma, urothelial carcinoma, and prostate cancer.
    • Identify clinical trials relating to these cancers, as well as the FDA-approved treatments for each.
    • Describe the rationale for common approaches to cancer immunotherapy.

     

    Faculty
    Mehmet Asim Bilen, MD

    Genitourinary Medical Oncologist

    Emory University, Atlanta, GA

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Mehmet Asim Bilen, MD - Consulting Fees: Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, and Sanofi; Grants to the institution - Xencor, Bayer, Bristol-Myers Squibb, Genetech/Roche, Seattle Genetics, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and Pfizer.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 11/1/2021 through 11/1/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.2 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-3074-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Genitourinary Malignancies
    Collapse Immunotherapy for the Treatment of Skin Cancers

    This course is no longer available for credit.

     

    Published 04/25/2022

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Skin Cancers, provides an overview of immunotherapy treatment for various forms of skin cancer. Multiple clinical trials are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for skin cancer.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  April 25, 2022 - April 25, 2023

     

    Estimated time to complete activity:  45 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Implement cancer immunotherapy treatment for skin cancer.
    • Identify FDA-approved immunotherapy treatments for skin cancer.
    • Describe the rationale for common approaches to cancer immunotherapy.

     

    Faculty
    Shailender Bhatia, MD

    Associate Professor of Medical Oncology

    University of Washington

    Fred Hutchison Cancer Research Center, Seattle, WA

     

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Shailender Bhatia, MD: Consulting Fees: Genentech, BMS, EMD-Serono, Sanofi-Genzyme, Exicure.   Contracted research: BMS, EMD-Serono, Immune Design, Merck, Novartis, Oncosec, Nantkwest, Exicure, Nektar, CheckMate, Xencor, Trisalus.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 04/25/2022 through 04/25/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.4 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-235-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Skin Cancers
    Collapse Toxicity Management

    This course is no longer available for credit.

     

    Published March 1, 2022

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    In this course, Toxicity Management, learners will be given information on the incidence, onset, severity and grading of immune-related toxicities; as well as immune-related adverse events with immune checkpoint inhibitors.  Dr. Jarushka Naidoo will also discuss cellular therapy adverse events and their management and discuss immunotherapy in special patient populations.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available: March , 2022 - March 1, 2023

     

    Estimated time to complete activity: 45 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify immune-related toxicities by grade, onset, and incidence.
    • Identify immune-related adverse events resulting from immune checkpoint inhibitors.
    • Describe the adverse events and management of cellular therapies.
    • Describe the precautions needed when immunotherapy is provided to special patient populations.

     

    Faculty
    Jarushka Naidoo, MBBCh

    Assistant Professor of Oncology and Attending Physician

    Sydney Kimmel Cancer Center, Johns Hopkins University

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Jarushka Naidoo, MBBCh: Consulting Fees: Astrazeneca, Bristol Meyers-Squibb, Roche/Genetech.  Non-CME Services: Merck,  Bristol Myers-Squibb, Astrazeneca.  Contracted Research: Astrazeneca, Merck.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 3/1/2022 through 03/01/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162 - 9999-22-083-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Toxicity Management
    Collapse Basic Principles of Cancer Immunotherapy

    This course is no longer available for credit.

    Published: March 1, 2022

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Basic Principles will walk the learner through the biological foundations of immunotherapy, types of immunotherapies, illustrate how biomarkers play a major role in immunotherapy, as well as cover the patient response to immunotherapy and subsequent physician assessment.  

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  March 1, 2022 - March 1, 2023

     

    Estimated time to complete activity:  45 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify key biological concepts of immunotherapy
    • Describe the various types of immunotherapy
    • Describe how biomakers play a key role in immunotherapy
    • Describe how to assess the patient response to immunotherapy

     

    Faculty
    Stefani Spranger, PhD

    Assistant Professor of Biology

    The Koch Institue for Integrative Cancer Research, Massachusetts Institue of Technology

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Stefani Spranger, PhD: Consulting Fees: Arcus, Tango, Takeda, Ribon, Merck, Dragonfly.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 3/1/2022 through 03/01/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-081-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Basic Principles of Cancer Immunotherapy
    Collapse Immunotherapy for the Treatment of Hematologic Malignancies

    This course is no longer available for credit.

     

    Published 6/25/2021

     

    Course description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Hematologic Malignancies, provides an overview of the various treatment approaches to hematologic malignancies. This module will provide an overview of the major immunotherapies in development, FDA-approved treatments as well as the side effects associated with those treatments, and current clinical trials.  Learners will have an opportunity to apply what they've learned through two case studies.  By the end of the course, participants will be better able to implement immunotherapy for the treatment of hematologic malignancies.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  June 25, 2021 - June 25, 2022

     

    Estimated time to complete activity: 45 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Discuss the purpose of immune checkpoint inihibitors, as well as identify which have been approved by the FDA.
    • Recognize antibody-drug conjugates (ADCs), which have been FDA-approved, and appropriate malignancies for which ADCs would be effective.
    • Identify bispecific antigens' role in immunotherapy.
    • Describe cellular therapies, including CAR T cell therapies and the side effects, current FDA approvals, and clinical trials in development.

     

    Faculty
    Hongtao Liu, MD, PhD

    Associate Professor of Medicine

    Co-Director, Combined Apheresis Unit

    Medical Director, Clinical Cellular Labratory Section of Hematology/Oncology

    Department of Medicine, University of Chicago

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Hongtao Liu, MD, PhD - Consulting Fees: Agios Pharmaceuticals; BeiGene, NGM Biopharmarmaceuticals. Contracted Research: BMS; Karyopharm, Miltenyi.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 6/25/2021 through 6/25/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-2839-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: June 23, 2021
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Hematologic Malignancies
    Collapse What

    This course is no longer available for credit.

     

    Published July 28, 2021

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, What's Next in Cancer Immunotherapy, provides an overview of several publications researching the conditions and stresses of the tumor microenvironment, as well as discussing some of the major factors impacting those providing and receiving immunotherapy treatments.  At the end of this course, participants have a better understanding not only of stress sensor impacting tumor cell growth, but also some of the major hurdles affecting immunotherapy's progression. 

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  July 28, 2021 - July 28, 2022

     

    Estimated time to complete activity: 45 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify three stress sensors impacting the endoplasmic reticulum.
    • Explain why targeting the cell's response to these stress sensors may be the key to immunotherapy treatments.
    • Identify several of the major hurdles impacting current and future cancer immunotherapy.

     

    Faculty
    Jessica Thaxton, PhD, MsCR

    Assistant Professor

    Hollings Cancer Center, Medical University of South Carolina

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Jessica Thaxton, PhD, MsCR: Research grants TEVA Pharmaceuticals

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 7/28/2021 through 7/28/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-2862-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: May 25, 2021
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO What
    Collapse Immunotherapy for the Treatment of Lung Cancer

    Originial publish date: May 21, 2021

    PLEASE NOTE: This course is no longer available for CE credit.  To see a list of courses available for credit, please click HERE for a complete listing.

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Lung Cancer, provides an overview of immunotherapy treatment for lung cancer. Multiple clinical trials dealing with both non-small cell lung cancer and small cell lung cancer are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for lung cancers.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  May 21, 2021 - May 21, 2022

     

    Estimated time to complete activity: 45 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Implement cancer immunotherapy treatment for lung cancer.
    • Identify immune-related toxicities related to lung cancer immunotherapy agents.
    • Describe the rationale for common approaches to cancer immunotherapy.

     

    Faculty
    Jennifer Carlisle, MD

    Assistant Professor

    Emory University

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Jennifer Carlisle, MD: Nothing to disclose.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 5/21/2021 through 5/21/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.4 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-2718-H01)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: May 21, 2021

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Lung Cancer
    Collapse Immunotherapy for the Treatment of Breast and Gynecologic Cancers

    Original publish date: May 13, 2021.  Please note: this course is no longer available for CE credits. 

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer's (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at https://www.sitcancer.org/education/aci/online.

     

    This course, Immunotherapy for the Treatment of Breast and Gynecologic Cancers, provides an overview of the currently-approved treatments used to treat both breast and gynecologic cancers, as well as a synopsis of future potential applications of immunotherapy for these cancers.  Several clinical trials and two case studies are discussed, allowing the learner to better understand the current use of immunotherapy as well as how clinical trials are leading the way to additional use of immunotherapy for both types of cancer.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

     

     

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available: May 13, 2021 - May 13, 2022

     

    Estimated time to complete activity: 30 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.


    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the early stage application of breast and gynecologic cancer immunotherapy treatment in relation to standard-of-care therapies
    • Select cancer immunotherapy treatment for breast and gynecologic cancer and better manage common side effects
    • Describe the rationale for common approaches to cancer immunotherapy

    Faculty
    Megan Kruse, MD

    Associate Staff Physician

    Hematology and Medical Oncology

    Cleveland Clinic

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

     

    Megan Kruse, MD: Consulting Fees: Puma biotechnology, Immunomedics, Eisai, Seattle Genetics, Lilly Oncology, Novartis Oncology.   Contracted Research: Tempus.

     

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 
     

    Method of Participation and Request for Credit
    During the period 5/13/2021 through 5/13/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-2714-H01-P)

    Type of Activity: Knowledge

     


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

     

    Original Course Date: May 13, 2021

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Breast and Gynecologic Cancers
    Collapse Navigating the Management of Triple-Negative Breast Cancer: Immunotherapy Considerations

    Navigating the Management of Triple-Negative Breast Cancer: Immunotherapy Considerations

    Join this interprofessional panel as they discuss the management of triple-negative breast cancer using immunotherapeutic agents.

     

    The goal of this initiative is to improve the knowledge and competence of oncologists, nurses/nurse practitioners (NPs), and pharmacists in safely and effectively implementing immune checkpoint inhibitors for eligible patients with triple-negative breast cancer (TNBC).

     

    This activity is intended for oncologists, obstetricians and gynecologists, pathologists, nurses, and pharmacists.

     

     

     

     

    Learning Objectives:

    • Have increased knowledge regarding the
      • Clinical trial data on the use of immune checkpoint inhibitor (ICI) regimens in patients with triple-negative breast cancer (TNBC) across the spectrum of disease
    • Have greater competence related to
      • Identifying patients who may be appropriate candidates for checkpoint inhibition
      • Using a team-based approach to managing immune-related adverse events of ICIs in TNBC

     

    Approximate Time to Complete: 45 minutes

     

    Credit Available: May 7, 2021 - May 7, 2022

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

     

    Additional Resources for Clinicans from SITC:

     

     

    Original Course Date: May 07, 2021

    Approved Credit:
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ANCC: 0.75 hours Contact Hour
  • ACPE: 0.75 hours CEU

  • MORE INFOMORE INFO Navigating the Management of Triple-Negative Breast Cancer: Immunotherapy Considerations
    Collapse Obtaining the Pieces to the Puzzle: Real-World Considerations in the First-Line Management of mNSCLC

    Obtaining the Pieces to the Puzzle: Real-World Considerations in the First-Line Management of mNSCLCDr. Ranee Mehra examines the use of immune checkpoint inhibitors in two patients with NSCLC. The goal of this activity is to improve clinicians' ability in managing patients with metastatic non-small cell lung cancer (mNSCLC) on immune checkpoint inhibitors (ICIs).

     

     

    The presented cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.

     

     

    This activity is intended for oncologists, pulmonologists, and pathologists.

     

     

     

     

    Learning Objectives:

    • Have increased knowledge regarding the
      • Clinical trial data on the use of ICIs in patients with mNSCLC whose tumor does not contain an actionable mutation
    • Have greater competence related to
      • Identifying the necessary immunotherapeutic biomarkers to help guide first-line treatment decisions in patients with mNSCLC without actionable mutations
      • Choosing the most appropriate first-line ICI regimen for a patient with mNSCLC without actionable mutations
      • Management of adverse events in patients receiving front-line therapy for mNSCLC without actionable mutations

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: April 20, 2021 - April 20, 2022

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

     

    Additional Resources for Clinicans from SITC:

     

     

     

    sitc-cig-rgb.png

    "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)" (Published July 17, 2018)

     

     

    View Guidelines Here.

    View On-Demand Webinar Here.

    Original Course Date: April 21, 2021

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Obtaining the Pieces to the Puzzle: Real-World Considerations in the First-Line Management of mNSCLC
    Collapse Everything You Need to Know About ICIs in Gynecologic Cancers

    Everything You Need to Know About ICIs in Gynecologic Cancers

    Join Dr. Yeku for a discussion on novel and emerging immunotherapeutic regimens for the management of gynecologic cancers.

     

    The goal of this activity is to explore and understand the rationale and current and potential role of immunotherapy in the treatment of gynecologic cancers.

     

    This activity is intended for oncologists, obstetricians, gynecologists, and pathologists.

     

     

     

     

    Learning Objectives:

    • Have increased knowledge regarding the
      • Clinical trial data around the use of immune checkpoint inhibitor (ICI) regimens in women with gynecological cancers
      • Role of immunotherapeutic biomarkers in women with gynecological cancers
      • Patients with gynecological cancer in whom an immune checkpoint inhibitor regimen should be considered

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: April 8, 2021 - April 8, 2022

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

     

    Additional Resources for Clinicans from SITC:

     

     

    Original Course Date: April 09, 2021

    Approved Credit:
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Everything You Need to Know About ICIs in Gynecologic Cancers
    Collapse Management of Bladder Cancer: Case Challenges

    Management of Bladder Cancer: Case Challenges

    Enhance your clinical skills as you engage with patients in an objective and realistic interactive simulation. Treat patients, diagnose medical conditions, and prescribe medications. There are no limits to your choices—order from thousands of labs, diagnoses, devices, and drugs using an intuitive patient chart-based interface. Powerful metrics track your performance and provide instant expert feedback on your decisions. Upon completion, results will be presented, along with author commentary on each case.

     

    The goal of this activity is to provide clinicians with the latest data and concepts regarding the diagnosis and treatment of and adverse event management for patients with bladder cancer.

     

    This activity is intended for hematology/oncology specialists and urologists.

     

     

     

     

    Learning Objectives:

    • Demonstrate improved performance associated with
      • Determining appropriate treatment strategies for bladder cancer
      • Selecting therapy for a patient with non-muscle invasive bladder cancer (NMIBC)
      • Selecting therapy for a patient with metastatic bladder cancer 
      • Providing strategies to monitor or manage immune-related adverse events 

     

    Approximate Time to Complete: 75 minutes

     

    Credit Available: March 29, 2021 - March 29, 2022

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

     

    Additional Resources for Clinicans from SITC:

     

     

    Original Course Date: April 08, 2021

    Approved Credit:
  • ACCME (MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)™
  • : 1.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Management of Bladder Cancer: Case Challenges
    Collapse Expanding the Role of Immunotherapy in the Treatment of Gastric/GEJ Cancers

    Expanding the Role of Immunotherapy in the Treatment of Gastric/GEJ CancersJoin Drs Catenacci and Uboha for an expert discussion on the role of immunotherapy in gastric/GEJ cancers.

     

    The goal of this activity is to inform clinicians about the current indications and guideline recommendations for immunotherapy in gastric/gastroesophageal junction cancers, and discuss ongoing clinical trials.

     

    This activity is intended for oncologists, gastroenterologists, and pathologists.

     

     

     

     

    Learning Objectives:

    • Have increased knowledge regarding the
      • Immunotherapy-based treatment in the management of gastric/GEJ cancers
    • Have greater competence related to
      • Identifying patients for immunotherapy-based treatment in the appropriate clinical setting reflective of biomarkers and previous treatments

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: April 5, 2021 - April 5, 2022

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

     

    Additional Resources for Clinicans from SITC:

     

     

    Original Course Date: April 08, 2021

    Approved Credit:
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Expanding the Role of Immunotherapy in the Treatment of Gastric/GEJ Cancers
    Collapse Essential Updates in GI Immunotherapy: HCC and Esophageal Cancers

    Essential Updates in GI Immunotherapy: HCC and Esophageal CancersIn this activity, join expert faculty for a discussion on emerging immunotherapy strategies for esophageal and hepatocellular carcinomas.

     

    The goal of this activity is to improve oncologists’ ability to integrate immune checkpoint inhibitors into the care of unresectable hepatocellular carcinoma (HCC) and esophageal cancer.

     

    This activity is intended for oncologists, gastroenterologists, and pathologists.

     

     

     

     

    Learning Objectives:

    • Have increased knowledge regarding the
      • Role of immunotherapy in esophageal cancer
      • Clinical data for immunotherapy use in unresectable HCC
    • Have greater competence related to the
      • Identification of appropriate candidates for treatment with immune checkpoint inhibitors in patients with HCC
      • Integration of immune checkpoint inhibitors for patients with esophageal cancer

     

    Approximate Time to Complete: 45 minutes

     

    Credit Available: March 19, 2021 - March 19, 2022

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

     

    Additional Resources for Clinicans from SITC:

     

     

    Original Course Date: March 18, 2021

    Approved Credit:
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Essential Updates in GI Immunotherapy: HCC and Esophageal Cancers
    Collapse Treatment Algorithms in Melanoma: Evaluating Where We Are and Where We Are Headed

    Treatment Algorithms in Melanoma: Evaluating Where We Are and Where We Are HeadedIn this activity, an interprofessional panel of experts discusses the roles of immunotherapies and biomarkers in the treatment of melanoma. The goal of this activity is to improve clinicians' awareness of current and emerging treatment approaches used in the management of patients with melanoma.

     

     

    This activity is intended for oncologists, dermatologists, emergency medicine specialists, nurses, and pharmacists.

     

     

     

     

    Learning Objectives:

    • Have increased knowledge regarding the
      • Emerging clinical trial data, including combination therapies (eg, tyrosine kinase inhibitors [TKIs] + immune checkpoint inhibitors [ICIs] and novel immunomodulating agents)
    • Have greater competence related to
      • Identifying appropriate treatment based on patients' disease factors, setting, and prior treatment history
    • Demonstrate greater confidence in their ability to
      • Coordinate with the interprofessional team to optimize care in patients with melanoma

     

    Approximate Time to Complete: 45 minutes

     

    Credit Available: March 12, 2021 - March 12, 2022

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

     

    Additional Resources for Clinicans from SITC:

     

     

     

    sitc-cig-rgb.png

    "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of cutaneous melanoma: version 2.0" (Published May 30, 2018)

     

    View Guidelines Here.

    View On-Demand Webinar Here.

    Original Course Date: March 15, 2021

    Approved Credit:
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ANCC: 0.75 hours Contact Hour
  • ACPE: 0.75 hours CEU

  • MORE INFOMORE INFO Treatment Algorithms in Melanoma: Evaluating Where We Are and Where We Are Headed
    Collapse Special Populations and Immune Checkpoint Inhibitors: Are They Safe?

    Special Populations and Immune Checkpoint Inhibitors: Are They Safe?In this activity, three experts discuss how to incorporate immune checkpoint inhibitor therapy into the management of individuals classified as part of the “special population” of patients not generally included in clinical trials.

     

    The goal of this activity is to educate clinicians on the use of immune checkpoint inhibitors in special populations.

     

    This activity is intended for hematology and oncology specialists, emergency medicine specialists, pulmonologists, nurses, pharmacists, and other healthcare professionals who treat and manage special populations not generally included in clinical trials.

     

     

     

     

    Learning Objectives:

    • Have increased knowledge regarding the
      • Emerging literature examining the use of immune checkpoint inhibitors (ICIs) in special populations, such as those with autoimmune disease
    • Have greater competence related to
      • Identifying when a patient with cancer from a special population may be considered for treatment with an ICI
      • Recognizing factors that may affect the safety and efficacy of ICIs in special populations

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: February 25, 2021 - February 25, 2022

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

     

    Additional Resources for Clinicans from SITC:

     

     

    Original Course Date: March 10, 2021

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ANCC: 0.50 hours Contact Hour
  • ACPE: 0.50 hours CEU

  • MORE INFOMORE INFO Special Populations and Immune Checkpoint Inhibitors: Are They Safe?
    Collapse Practical Barriers in Cancer Immunotherapy Treatment

    This course is no longer available for continuing education credit.

     

    Published February 23, 2021

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Practical Barriers in Cancer Immunotherapy Treatment, provides a detailed overview of how to overcome barriers to obtaining reimbursement from both Medicare and commercial payers for the use of immunotherapy in cancer treatment.
     

    At the end of this course, participants will be able to identify solutions to overcome both operational and financial barriers to integrating immunotherapy into their practice setting.

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.


    Faculty
    Sigrun Hallmeyer, MD

    Medical Director, Cancer Service Line

    Medical Director, Cancer Survivorship Center

    Advocate Lutheran General Hospital

    Chair, Executive Committee

    Association of Community Cancer Centers, Immuno-Oncology Institute


     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify and implement solutions to overcome operational barriers to implementing cancer immunotherapy in the clinical setting. 
    • Identify and implement solutions to overcome financial barriers to implementing cancer immunotherapy in the clinical setting.

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     


    Continuing Education Information

     

    Credit Available: February 23, 2021 - February 23, 2022

     

    Estimated time to complete activity: 1.25 hours

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-2606-H01-P)

    Type of Activity: Application


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Sigrun Hallmeyer, MD: Consulting Fees: Bristol Myers Squibb; Cardinal Health; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: Bristol Myers Squibb

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 



    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: February 23, 2021

    Approved Credit:
  • ACPE: 1.25 hours Contact Hour
  • ANCC: 1.25 hours Contact Hour
  • ACCME (MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 1.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Practical Barriers in Cancer Immunotherapy Treatment
    Collapse Steps and Considerations to Optimizing Management of Recurrent/Metastatic Head and Neck Cancer

    The goal of this activity is to improve clinicians' ability to manage patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). The two cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.

     

    This activity is intended for oncologists, pathologists, and surgeons.

     

     

    Learning Objectives:

    • Have increased knowledge regarding the
      • Clinical trial design and data from recent trials for recurrent or metastatic HNSCC
    • Have greater competence related to
      • Identifying patient and tumor characteristics that can help guide treatment selection in patients with recurrent or metastatic HNSCC across the disease spectrum
      • Developing an evidence-based treatment plan for a patient with recurrent or metastatic HNSCC across the disease spectrum
      • Recognizing and mitigating treatment- and immune-related adverse events (irAEs)

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: January 25, 2021 - January 25, 2022

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

     

    Additional Resources for Clinicans from SITC:

     

     

     

    sitc-cig-rgb.png

    "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)" (Published July 15, 2019)

     

     

    View Guidelines Here.

    View On-Demand Webinar Here.

    Original Course Date: February 08, 2021

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Steps and Considerations to Optimizing Management of Recurrent/Metastatic Head and Neck Cancer
    Collapse Updates on Immune Modulators in Lung Cancer: Have We Met the Need?

    https://img.medscapestatic.com/thumbnail_library/943953.jpg?interpolation=lanczos-none&resize=300:*

     

    This activity is intended for hematologists/oncologists, pulmonologists, and pathologists.

     

    The goal of this activity is to increase clinicians' understanding of timmune modulators used in the management of patients with metastatic non-small cell lung cancer (NSCLC)

     

     

     

     

     

     

    Learning Objectives:

    • Have increased knowledge regarding the mmune modulators being studied to treat patients with metastatic NSCLC (mNSCLC), including how they may manipulate the immune system to improve recognition of cancer cells, tumors, and metastases

    • Have increased knowledge regarding the ongoing immunotherapy clinical trials in the management of patients with mNSCLC

     

    Approximate Time to Complete: 15 minutes

     

    Credit Available: January 13, 2021 - January 13, 2022

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

     

    Additional Resources for Clinicans from SITC:

    Certificate in Cancer Immunotherapy

     

     

    Original Course Date: January 13, 2021

    Approved Credit:
  • : 0.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 0.25 hours AMA PRA Category 1 Credit(s)™

  • MORE INFOMORE INFO Updates on Immune Modulators in Lung Cancer: Have We Met the Need?
    ACI 2020-21 Online Interactive Courses
    Collapse Basic Principles of Cancer Immunotherapy

    This course is no longer available for credit.

    Published: March 1, 2022

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Basic Principles will walk the learner through the biological foundations of immunotherapy, types of immunotherapies, illustrate how biomarkers play a major role in immunotherapy, as well as cover the patient response to immunotherapy and subsequent physician assessment.  

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  March 1, 2022 - March 1, 2023

     

    Estimated time to complete activity:  45 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify key biological concepts of immunotherapy
    • Describe the various types of immunotherapy
    • Describe how biomakers play a key role in immunotherapy
    • Describe how to assess the patient response to immunotherapy

     

    Faculty
    Stefani Spranger, PhD

    Assistant Professor of Biology

    The Koch Institue for Integrative Cancer Research, Massachusetts Institue of Technology

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Stefani Spranger, PhD: Consulting Fees: Arcus, Tango, Takeda, Ribon, Merck, Dragonfly.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 3/1/2022 through 03/01/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-081-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Basic Principles of Cancer Immunotherapy
    Collapse Immunotherapy for the Treatment of Genitourinary Malignancies

    This course is no longer available for credit.

    Published 11/1/2021

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Genitourinary Malignancies, provides an overview of immunotherapy treatment for renal cell carcinoma, urothelial carcinoma, and prostate cancer. Multiple clinical trials dealing with all three cancer types are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for these cancers.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available: November 1, 2021 - November 1, 2022

     

    Estimated time to complete activity:  30 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Implement cancer immunotherapy treatment for renal cell carcinoma, urothelial carcinoma, and prostate cancer.
    • Identify clinical trials relating to these cancers, as well as the FDA-approved treatments for each.
    • Describe the rationale for common approaches to cancer immunotherapy.

     

    Faculty
    Mehmet Asim Bilen, MD

    Genitourinary Medical Oncologist

    Emory University, Atlanta, GA

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Mehmet Asim Bilen, MD - Consulting Fees: Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, and Sanofi; Grants to the institution - Xencor, Bayer, Bristol-Myers Squibb, Genetech/Roche, Seattle Genetics, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and Pfizer.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 11/1/2021 through 11/1/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.2 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-3074-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Genitourinary Malignancies
    Collapse Immunotherapy for the Treatment of Gastrointestinal Cancers

    This course is no longer available for credit.

    Published: 3/1/2022

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Gastrointestinal Cancers, provides an overview of immunotherapy treatment for hepatocellular, colorectal, and other gastrointestinal malignancies. Multiple clinical trials dealing with these types of cancer are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for gastrointestinal cancers.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  March 1, 2022 - March 1, 2023

    Estimated time to complete activity:  30 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Implement cancer immunotherapy treatment for gastrointestinal cancer.
    • Identify various studies that are stil ongoing as well as completed clinical trials which have resulted in approvals by disease state.
    • Describe the rationale for common approaches to cancer immunotherapy.

     

    Faculty
    Aiwu Ruth He, MD, PhD

    Associate Professor of Medicine, Medstar Georgetown University Hospital

    Georgetown University

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Aiwu Ruth He, MD, PhD:  Consulting Fees: Merck, Bayer, BMS, Aztrazeneca; Fees for Non-CE Service: Eisai, BMS, Exelixis; Contracted Research: Merck, Genentech

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 3/1/2022 through 03/01/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number  - JA4008162-9999-22-082-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Gastrointestinal Cancers
    Collapse Immunotherapy for the Treatment of Microsatellite Instability or Tumor Mutation Burden - High Cancers

    This course is no longer available for credit.

    Published 10/07/2021

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Microsatellite Instability or Tumor Mutational Burden-High Cancers, provides an overview of immunotherapy treatment for cancers with these characteristics. This course will help the learner understand what microsatellite instability (MSI)  and tumor mutational burden (TMB) terms mean, what meaures can be performed to identify MSI/TMB, various FDA-approved regimens for cancers that are MSI/TMB-high, and provide current clinical trial information.    Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy for the treatment of cancers with high or low microsatellite instability and/or tumor mutational burden.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available: October 7, 2021 - October 7, 2022

     

    Estimated time to complete activity: 30 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Define the meaning of microsatellite instability and tumor mutational burden.
    • Identify the methods used to measure MSI or TMB.
    • Describe the rationale for common approaches to cancer immunotherapy with MSI/TMB measures identified.

     

    Faculty
    Dung Le, MD

    Associate Professor, GI Medical Oncology

    Sydney Kimmel Cancer Care Center, Johns Hopkins University

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Dung Le, MD: Consulting Fees: Merck, Bristol Myers Squibb, Janssen, Nouscom.   Contracted Research: Merck, Bristol Myers Squibb, Aduro Biotech, Medivir, Curegenix, Nouscom

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 10/7/2021 through 10/7/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-3027-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Microsatellite Instability or Tumor Mutation Burden - High Cancers
    Collapse Toxicity Management

    This course is no longer available for credit.

     

    Published March 1, 2022

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    In this course, Toxicity Management, learners will be given information on the incidence, onset, severity and grading of immune-related toxicities; as well as immune-related adverse events with immune checkpoint inhibitors.  Dr. Jarushka Naidoo will also discuss cellular therapy adverse events and their management and discuss immunotherapy in special patient populations.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available: March , 2022 - March 1, 2023

     

    Estimated time to complete activity: 45 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify immune-related toxicities by grade, onset, and incidence.
    • Identify immune-related adverse events resulting from immune checkpoint inhibitors.
    • Describe the adverse events and management of cellular therapies.
    • Describe the precautions needed when immunotherapy is provided to special patient populations.

     

    Faculty
    Jarushka Naidoo, MBBCh

    Assistant Professor of Oncology and Attending Physician

    Sydney Kimmel Cancer Center, Johns Hopkins University

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Jarushka Naidoo, MBBCh: Consulting Fees: Astrazeneca, Bristol Meyers-Squibb, Roche/Genetech.  Non-CME Services: Merck,  Bristol Myers-Squibb, Astrazeneca.  Contracted Research: Astrazeneca, Merck.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 3/1/2022 through 03/01/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162 - 9999-22-083-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Toxicity Management
    Collapse Immunotherapy for the Treatment of Skin Cancers

    This course is no longer available for credit.

     

    Published 04/25/2022

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Skin Cancers, provides an overview of immunotherapy treatment for various forms of skin cancer. Multiple clinical trials are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for skin cancer.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  April 25, 2022 - April 25, 2023

     

    Estimated time to complete activity:  45 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Implement cancer immunotherapy treatment for skin cancer.
    • Identify FDA-approved immunotherapy treatments for skin cancer.
    • Describe the rationale for common approaches to cancer immunotherapy.

     

    Faculty
    Shailender Bhatia, MD

    Associate Professor of Medical Oncology

    University of Washington

    Fred Hutchison Cancer Research Center, Seattle, WA

     

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Shailender Bhatia, MD: Consulting Fees: Genentech, BMS, EMD-Serono, Sanofi-Genzyme, Exicure.   Contracted research: BMS, EMD-Serono, Immune Design, Merck, Novartis, Oncosec, Nantkwest, Exicure, Nektar, CheckMate, Xencor, Trisalus.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 04/25/2022 through 04/25/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.4 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-235-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Skin Cancers
    Collapse Immunotherapy for the Treatment of Hematologic Malignancies

    This course is no longer available for credit.

     

    Published 6/25/2021

     

    Course description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Hematologic Malignancies, provides an overview of the various treatment approaches to hematologic malignancies. This module will provide an overview of the major immunotherapies in development, FDA-approved treatments as well as the side effects associated with those treatments, and current clinical trials.  Learners will have an opportunity to apply what they've learned through two case studies.  By the end of the course, participants will be better able to implement immunotherapy for the treatment of hematologic malignancies.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  June 25, 2021 - June 25, 2022

     

    Estimated time to complete activity: 45 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Discuss the purpose of immune checkpoint inihibitors, as well as identify which have been approved by the FDA.
    • Recognize antibody-drug conjugates (ADCs), which have been FDA-approved, and appropriate malignancies for which ADCs would be effective.
    • Identify bispecific antigens' role in immunotherapy.
    • Describe cellular therapies, including CAR T cell therapies and the side effects, current FDA approvals, and clinical trials in development.

     

    Faculty
    Hongtao Liu, MD, PhD

    Associate Professor of Medicine

    Co-Director, Combined Apheresis Unit

    Medical Director, Clinical Cellular Labratory Section of Hematology/Oncology

    Department of Medicine, University of Chicago

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Hongtao Liu, MD, PhD - Consulting Fees: Agios Pharmaceuticals; BeiGene, NGM Biopharmarmaceuticals. Contracted Research: BMS; Karyopharm, Miltenyi.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 6/25/2021 through 6/25/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-2839-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: June 23, 2021
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Hematologic Malignancies
    Collapse What

    This course is no longer available for credit.

     

    Published July 28, 2021

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, What's Next in Cancer Immunotherapy, provides an overview of several publications researching the conditions and stresses of the tumor microenvironment, as well as discussing some of the major factors impacting those providing and receiving immunotherapy treatments.  At the end of this course, participants have a better understanding not only of stress sensor impacting tumor cell growth, but also some of the major hurdles affecting immunotherapy's progression. 

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  July 28, 2021 - July 28, 2022

     

    Estimated time to complete activity: 45 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify three stress sensors impacting the endoplasmic reticulum.
    • Explain why targeting the cell's response to these stress sensors may be the key to immunotherapy treatments.
    • Identify several of the major hurdles impacting current and future cancer immunotherapy.

     

    Faculty
    Jessica Thaxton, PhD, MsCR

    Assistant Professor

    Hollings Cancer Center, Medical University of South Carolina

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Jessica Thaxton, PhD, MsCR: Research grants TEVA Pharmaceuticals

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 7/28/2021 through 7/28/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-2862-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: May 25, 2021
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO What
    Collapse Immunotherapy for the Treatment of Lung Cancer

    Originial publish date: May 21, 2021

    PLEASE NOTE: This course is no longer available for CE credit.  To see a list of courses available for credit, please click HERE for a complete listing.

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Lung Cancer, provides an overview of immunotherapy treatment for lung cancer. Multiple clinical trials dealing with both non-small cell lung cancer and small cell lung cancer are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for lung cancers.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  May 21, 2021 - May 21, 2022

     

    Estimated time to complete activity: 45 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Implement cancer immunotherapy treatment for lung cancer.
    • Identify immune-related toxicities related to lung cancer immunotherapy agents.
    • Describe the rationale for common approaches to cancer immunotherapy.

     

    Faculty
    Jennifer Carlisle, MD

    Assistant Professor

    Emory University

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Jennifer Carlisle, MD: Nothing to disclose.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 5/21/2021 through 5/21/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.4 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-2718-H01)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: May 21, 2021

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Lung Cancer
    Collapse Immunotherapy for the Treatment of Breast and Gynecologic Cancers

    Original publish date: May 13, 2021.  Please note: this course is no longer available for CE credits. 

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer's (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at https://www.sitcancer.org/education/aci/online.

     

    This course, Immunotherapy for the Treatment of Breast and Gynecologic Cancers, provides an overview of the currently-approved treatments used to treat both breast and gynecologic cancers, as well as a synopsis of future potential applications of immunotherapy for these cancers.  Several clinical trials and two case studies are discussed, allowing the learner to better understand the current use of immunotherapy as well as how clinical trials are leading the way to additional use of immunotherapy for both types of cancer.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

     

     

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available: May 13, 2021 - May 13, 2022

     

    Estimated time to complete activity: 30 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.


    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the early stage application of breast and gynecologic cancer immunotherapy treatment in relation to standard-of-care therapies
    • Select cancer immunotherapy treatment for breast and gynecologic cancer and better manage common side effects
    • Describe the rationale for common approaches to cancer immunotherapy

    Faculty
    Megan Kruse, MD

    Associate Staff Physician

    Hematology and Medical Oncology

    Cleveland Clinic

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

     

    Megan Kruse, MD: Consulting Fees: Puma biotechnology, Immunomedics, Eisai, Seattle Genetics, Lilly Oncology, Novartis Oncology.   Contracted Research: Tempus.

     

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 
     

    Method of Participation and Request for Credit
    During the period 5/13/2021 through 5/13/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-2714-H01-P)

    Type of Activity: Knowledge

     


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

     

    Original Course Date: May 13, 2021

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Breast and Gynecologic Cancers
    Collapse Practical Barriers in Cancer Immunotherapy Treatment

    This course is no longer available for continuing education credit.

     

    Published February 23, 2021

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Practical Barriers in Cancer Immunotherapy Treatment, provides a detailed overview of how to overcome barriers to obtaining reimbursement from both Medicare and commercial payers for the use of immunotherapy in cancer treatment.
     

    At the end of this course, participants will be able to identify solutions to overcome both operational and financial barriers to integrating immunotherapy into their practice setting.

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.


    Faculty
    Sigrun Hallmeyer, MD

    Medical Director, Cancer Service Line

    Medical Director, Cancer Survivorship Center

    Advocate Lutheran General Hospital

    Chair, Executive Committee

    Association of Community Cancer Centers, Immuno-Oncology Institute


     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify and implement solutions to overcome operational barriers to implementing cancer immunotherapy in the clinical setting. 
    • Identify and implement solutions to overcome financial barriers to implementing cancer immunotherapy in the clinical setting.

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     


    Continuing Education Information

     

    Credit Available: February 23, 2021 - February 23, 2022

     

    Estimated time to complete activity: 1.25 hours

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-2606-H01-P)

    Type of Activity: Application


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Sigrun Hallmeyer, MD: Consulting Fees: Bristol Myers Squibb; Cardinal Health; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: Bristol Myers Squibb

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 



    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: February 23, 2021

    Approved Credit:
  • ACPE: 1.25 hours Contact Hour
  • ANCC: 1.25 hours Contact Hour
  • ACCME (MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 1.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Practical Barriers in Cancer Immunotherapy Treatment
    Collapse Mechanisms of Immune-Related Adverse Events

    Please note: this course is no longer eligible for continuing education credits.

     

    Published December 24, 2020

     

    Course Description

    This interactive course provides an overview of the mechanisms by which cancer immunotherapy may activate immune-related adverse events (irAEs). The foundational knowledge presented in this course is critical to understanding how and why immune-related adverse events occur and how they can be treated.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.


    Faculty
    Pradnya Patil, MD, FACP

    Hematology/Oncology Fellow

    Taussig Cancer Institute, Cleveland Clinic


     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Discuss the mechanisms of peripheral and central immune tolerance.
    • Describe the biological pathways involved in mediating autoimmune reactions.
    • Explain the differences between PD-1 and CTLA-4 pathway-mediated autoimmunity.

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     


    Continuing Education Information

     

    Credit Available: December 24, 2020 - December 24, 2021

     

    Estimated time to complete activity: 0.5 hour

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2520-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.  Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Pradnya Patil, MD, FACP: Nothing to disclose

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: December 24, 2020

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Mechanisms of Immune-Related Adverse Events
    2020 Courses
    Collapse Immunotherapy for the Treatment of Hepatocellular Carcinoma

    This course is no longer available for credit.

    Originally published May 26, 2020 (Updated June 9. 2020)

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Hepatocellular Carcinoma (HCC), provides an overview of liver immunobiology and immunotherapeutic strategies in HCC, including checkpoint inhibition, blocking inhibitory cytokines, vaccine therapies, oncolytic viruses, and adoptive cell therapy. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for HCC.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Anuradha Krishnamurthy, MD
    Assistant Professor of Medicine
    University of Pittsburgh School of Medicine
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the characteristics of liver immunobiology
    • Implement cancer immunotherapy treatment for HCC and better manage common side effects
    • Describe the rationale for common approaches to cancer immunotherapy
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 5/26/20 - 5/26/21

    Approximate Time to Complete:  45 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2142-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Anuradha Krishnamurthy, MD: Nothing to disclose


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 5/26/20 through 5/26/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Hepatocellular Carcinoma.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: May 26, 2020

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Hepatocellular Carcinoma
    Collapse Immunotherapy for the Treatment of Skin Cancers

    This course is no longer available for credit. 

    Published May 26, 2020

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Skin Cancers, provides the latest in immunotherapy treatment for skin cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for skin cancers.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Ryan J. Sullivan, MD
    Assistant Professor of Medicine
    Harvard Medical School, Boston, MA
    Division of Hematology/Oncology, Department of Medicine
    Massachusetts General Hospital, Boston MA

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy.
    • Implement cancer immunotherapy treatment for skin cancers. 
    • Identify common side effects of immunotherapy agents.
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 5/26/20 - 5/26/21

    Approximate Time to Complete:  75 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (.125 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2143-H01-P)

    Type of Activity: Application


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.3 contact hours. Designated for 1.0 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Ryan J. Sullivan, MD: Consulting Fees (Merck, Novartis, Replimune, Bristol Myers Squibb, Asana Biosciences); Contracted Research (Merck, Amgen)


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 5/26/20 through 5/26/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Skin Cancers.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: May 26, 2020

    Approved Credit:
  • ACPE: 1.25 hours Contact Hour
  • ANCC: 1.30 hours Contact Hour
  • ACCME (MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 1.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Skin Cancers
    Collapse Immunotherapy for the Treatment of Head and Neck Cancer

    Originally published April 30, 2020 (updated May 7, 2020)

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Head and Neck Cancer, provides an overview of immunotherapy treatment for head and neck cancer. Multiple clinical trials are discussed, including both mono- and combination therapies.  Learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for head and neck cancer.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Michael Gibson, MD, PhD FACP
    Associate Professor of Medicine
    Director of Translational Research for Head and Neck Oncology
    Director of Translational Therapeutics for Esophago-Gastric Oncology
    Vanderbilt-Ingram Cancer Center
    Vanderbilt University Medical Center
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe rationale for common approaches to cancer immunotherapy.
    • Implement cancer immunotherapy treatments for head and neck cancers. 
    • Identify appropriate clinical management of common side effects of immunotherapy agents. 
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 4/30/20 - 4/30/21

    Approximate Time to Complete:  45 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2066-H01-P)

    Type of Activity: Application


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Michael Gibson, MD, PhD: Consulting fees to Merck, Bristol-Myers Squibb; Fees for Non-CME/CE services received directly from a commercial interest or their agents to Bristol-Myers Squibb (non-branded)


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 4/30/20 through 4/30/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Head and Neck Cancer.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Firefox, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: April 30, 2020

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Head and Neck Cancer
    Collapse Immunotherapy for the Treatment of Genitourinary Malignancies

    This course is no longer available for credit.  Please refer to the newest version of Immunotherapy for the Treatement of Genitourinary Malignancies, published on 11/1/2021.

    Originally published March 31, 2020 (updated May 7, 2020)

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Genitourinary Malignancies, provides an overview of immunotherapy treatment for the genitourinary malignancies renal cell carcinoma, urothelial carcinoma, and prostate cancer. Multiple clinical trials are discussed, including both mono- and combination therapies.  Learners will have an opportunity to interactively apply what they've learned through three case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for genitourinary malignancies.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Pedro Barata, MD, MSc
    Assistant Professor of Medicine
    Deming Department of Medicine
    Section of Hematology/Oncology
    Tulane University School of Medicine
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe rationale for common approaches to cancer immunotherapy.
    • Implement cancer immunotherapy treatments for genitourinary malignancies. 
    • Identify appropriate clinical management of common side effects of immunotherapy agents. 
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 3/31/20 - 3/31/21

    Approximate Time to Complete:  1 hour
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     


    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2051-H01-P)

    Type of Activity: Application


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.8 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Pedro Barata, MD, MSc: Consulting Fees (Exelixis, Caris, Bayer, Janssen, EMD-Serono, Pfizer, Astellas, Dendreon, Clovis, Eisai, Sanofi); Contracted Research (BlueEarth Diagnostics, Nektar, AstraZeneca and Seattle Genetics)


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 3/31/20 through 3/31/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Genitourinary Malignancies.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Firefox, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: March 31, 2020

    Approved Credit:
  • ACPE: 1 hour Contact Hour
  • ANCC: 1 hour Contact Hour
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Genitourinary Malignancies
    Collapse What

    This version of the course is no longer available for credit.  To access the accredited version, go here to find the What's Next in Cancer Immunotherapy that is a CME-, CPE-, CNE-, and MOC-certified activity.

     

    Published February 11, 2020

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, What's Next for Cancer Immunotherapy?, covers the future of cancer immunotherapy such as understanding important trends, new developments, potential approvals and disease states with promising data.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Evan J. Lipson, MD
    Associate Professor, Department of Oncology
    Johns Hopkins University School of Medicine

    Parul Agarwal, MD
    Medical Oncology Fellow
    Johns Hopkins University School of Medicine
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale behind expanding the settings in which cancer immunotherapy is administered, including patients with a larger variety of tumor types and patient populations previously excluded from clinical trial participation.
    • Describe the basis for novel immunotherapy drug combinations.
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 2/11/20 - 2/11/21

    Approximate Time to Complete:  45 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-1083-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.4 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Evan J. Lipson, MD: Consultant (Bristol-Myers Squibb, Novartis, EMD Serono, Array BioPharma, Macrogenics, Merck); Contracted Research (Bristol-Myers Squibb, Merck)
     

    Parul Agarwal, MD: Nothing to Disclose


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 2/11/20 through 2/11/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for What's Next for Cancer Immunotherapy?
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: February 11, 2020

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO What
    Collapse Expert Insights on Emerging Data for the Use of Immunotherapy in Advanced RCC

    Access Course

     

    Expert Insights on Emerging Data for the Use of Immunotherapy in Advanced RCCWatch experts discuss the latest data in immunotherapy as well as strategies for managing patients with advanced RCC.

     

    This activity is intended for oncologists, urologists, nephrologists, nurses and nurse practitioners, pharmacists, and other healthcare providers who manage patients with renal cell carcinoma (RCC).

     

    The goal of this activity is to increase understanding of the latest advances in the use of checkpoint inhibition in patients with advanced RCC.

     

    Learning Objectives:

    • Have increased knowledge regarding the emerging clinical trial data on the use of immune checkpoint inhibitors (ICIs) and other immunotherapies alone or in combination in the treatment of advanced RCC
    • Have increased knowledge regarding the impact of recent clinical data on the treatment paradigm for patients with advanced RCC
    • Demonstrate greater confidence in their ability to work with the interprofessional team to recognize and mitigate adverse events (AEs) in patients with advanced RCC

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Jan. 30, 2020 - Jan. 30, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Lung Cancer Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)" (Published December 20, 2019)

     

     

     

    View Guidelines Here.

    View On-demand Webinar Here.

    Original Course Date: January 30, 2020

    Approved Credit:
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ANCC: 0.50 hours Contact Hour
  • ACPE: 0.05 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™

  • MORE INFOMORE INFO Expert Insights on Emerging Data for the Use of Immunotherapy in Advanced RCC
    Collapse Immunotherapy for the Treatment of Hematologic Malignancies

    Please note this course is no longer available for credit.   Click here to access the current version of Immunotherapy for the Treatment of Hematologic Malignancies which is a CME-, CPE-, CNE-, and MOC-certified activity.

     

    Originally published January 23, 2020 (Updated May 7, 2020)

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Hematologic Malignancies, provides the latest in immunotherapy treatment for hematological cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for hematologic cancers.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Bhagirathbhai R. Dholaria, MBBS
    Assistant Professor
    Department of Hematology - Oncology
    Vanderbilt University School of Medicine, Nashville, TN
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy.
    • Implement cancer immunotherapy treatment for hematologic cancers. 
    • Identify common side effects of immunotherapy agents.
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 1/23/20 - 1/23/21

    Approximate Time to Complete:  45 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-1072-H01-P)

    Type of Activity: Application


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hours. Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Bhagirathbhai R. Dholaria, MBBS: Celgene (consulting)


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 1/23/20 through 1/23/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Hematologic Malignancies.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: January 23, 2020

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.80 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Hematologic Malignancies
    Collapse Updates in the Role of Immune Checkpoint Inhibitors for the Management of RCC

    Access Course

     

    Updates in the Role of Immune Checkpoint Inhibitors for the Management of RCCDrs Pal and Hammers discuss data and clinical pearls for the use of checkpoint inhibitors in RCC.

     

    This activity is intended for hematologists/oncologists and urologists.

     

    The goal of this activity is to improve knowledge and competence related to the role of immune checkpoint inhibitors (ICIs) as monotherapy and combination therapy for patients with renal cell carcinoma (RCC).

     

    Learning Objectives:

    • Have increased knowledge regarding the clinical trial data related to ICIs for the treatment of RCC
    • Have greater competence related to selecting patients with RCC who are appropriate candidates to receive ICI therapy

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Jan. 21, 2020 - Jan. 21, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)" (Published December 20, 2019)

     

     

     

    View Guidelines Here.

    View On-demand Webinar Here.

    Original Course Date: January 21, 2020

    Approved Credit:
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Updates in the Role of Immune Checkpoint Inhibitors for the Management of RCC
    Collapse Toxicity Management

    Published January 16, 2020

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Toxicity Management, provides an overview of clinical toxicity management for cancer immunotherapy. Both common and uncommon immune-related adverse events (irAEs) are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to manage immune-related adverse events for patients receiving cancer immunotherapy.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Morgan Gwynn, PharmD, BCOP, CPP
    Melanoma and Head & Neck Oncology Clinical Pharmacist Practitioner
    University of North Carolina Medical Center
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify common and uncommon immune-related adverse events associated with cancer immunotherapy
    • Describe best practices for managing common side effects seen in cancer immunotherapy treatment

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 1/16/20-1/16/21

    Approximate Time to Complete:  45 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-1068-H01-P)

    Type of Activity: Application


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hour.  Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Morgan Gwynn, PharmD, BCOP, CPP: Nothing to disclose


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 1/16/20 through 1/16/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Toxicity Management.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: January 16, 2020

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.80 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Toxicity Management
    2019 Courses
    2018 Courses
    Collapse Challenges and Opportunities: Steps to Maximizing Cancer Immunotherapy Regimens

    Access Course

     

    Experts discuss the latest research in the use of cancer immunotherapies.

     

    This activity is intended for oncologists, pathologists, dermatologists, and other healthcare professionals who manage patients with cancer.

     

    The goal of this activity is to discuss emerging strategies in the use of immunotherapy for cancer treatment.

     

     

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 19, 2018- Dec. 19, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 19, 2018

    Approved Credit:
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™

  • MORE INFOMORE INFO Challenges and Opportunities: Steps to Maximizing Cancer Immunotherapy Regimens
    Collapse Cases in mRCC: Steps to Optimizing Care

    Access Course

    Cases in mRCC: Steps to Optimize CareDr Monty Pal explores the role of immunotherapy in 2 patients with advanced renal cell carcinoma (RCC).

     

    This activity is intended for oncologists, urologists, nephrologists, nurses, pharmacists, and other healthcare professionals who manage patients with renal cell carcinoma (RCC).

     

    The goal of this activity is to evaluate the latest understanding of the role of immunotherapy in patients with advanced RCC.

     

     

    Approximate Time to Complete: 1 hour

     

    Course Available Beginning: Dec. 19, 2018 -  Dec. 19, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 19, 2018

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • ACPE: 1 hour CEU
  • ABIM: 1 hour ABIM MOC Part 2 Credits
  • ANCC: 1 hour Contact Hour

  • MORE INFOMORE INFO Cases in mRCC: Steps to Optimizing Care
    Collapse Advancing the Care of Patients with SCLC: Emerging Treatment Options

    Access Course

     

    Emerging Opportunities for Immunotherapy in Small Cell Lung CancerDr Charles Rudin discusses the latest data on the use of checkpoint inhibition in patients with SCLC.

     

    This activity is intended for oncologists, pulmonologists, and pathologists.

     

    The goal of this activity is to review the latest advances in the use of immune checkpoint inhibition in patients with small cell lung cancer (SCLC).

     

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Credit Available: Dec. 18, 2018- Dec. 18, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 18, 2018

    Approved Credit:
  • ABIM: 0.25 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.25 hours AMA PRA Category 1 Credit(s)™

  • MORE INFOMORE INFO Advancing the Care of Patients with SCLC: Emerging Treatment Options
    Collapse Case Studies in Clinical Decision Making in mCRC

    Access Course

     

    The use and challenges of immunotherapy in patients with MSI-H CRC is explored through 2 cases.

     

    This activity is intended for oncologists, gastroenterologists, surgeons, nurses, pharmacists, and other healthcare professionals who treat patients with colorectal cancer (CRC).

     

    The goal of this activity is to examine the management of microsatellite instability-high (MSI-H) CRC, including testing and treatment with immunotherapy.

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 18, 2018 - Dec. 18, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 18, 2018

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • ABIM: 1 hour ABIM MOC Part 2 Credits
  • ACPE: 1 hour CEU
  • ANCC: 1 hour Contact Hour

  • MORE INFOMORE INFO Case Studies in Clinical Decision Making in mCRC
    Collapse Adjuvant Therapy in Melanoma: What Is It and Is It Right For Me?

    Access Course

    This article is for people who want to understand how biomarkers may affect their cancer treatment choices. It's also for their care partners, and others who want to learn more about the topic. The goal is to help you know what to discuss with your healthcare team about testing for biomarkers and what the results mean for your treatment.

     

     

     

     

     

     

     

    You'll explore:

    • What adjuvant therapy in melanoma is
    • Who adjuvant therapy is recommended for
    • The potential benefits of adjuvant therapy
    • About side effects of adjuvant therapy
    • Questions to ask your provider about adjuvant therapy

     

    Available beginning: Dec. 18, 2018

     

    Approximate Time to Complete: 30 minutes

     

     

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 18, 2018
    MORE INFOMORE INFO Adjuvant Therapy in Melanoma: What Is It and Is It Right For Me?
    Collapse Practice Your Skills: Managing Patients with Advanced NSCLC

    Access Course

     

    Practice Your Skills: Managing Patients With Advanced NSCLCApply best practices to assess, treat, and educate patients with advanced NSCLC.

     

    This activity is intended for hematology/oncology specialists, pulmonologists, and pathologists.

     

    The goal of this activity is to build physician confidence in identifying and ordering appropriate evidence-based treatment regimens and providing patient education.

     

     

     

     

     

     

    Approximate Time to Complete: 1 hour

     

    Credit Available: Dec. 13, 2018- Dec. 13, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 13, 2018

    Approved Credit:
  • ABIM: 1 hour ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

  • MORE INFOMORE INFO Practice Your Skills: Managing Patients with Advanced NSCLC
    Collapse Immune Checkpoint Inhibitors in Lung Cancer: No Longer The Road Less Traveled?

    Access Course

     

    Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Experts discuss emerging clinical trial data on the use of immune checkpoint inhibitors in the management of advanced lung cancers.

     

    This activity is intended for  oncologists, pulmonologists, and pathologists.

     

    The goal of this activity is to discuss how to integrate emerging clinical trial data on the use of immune checkpoint inhibitors into the management of patients with advanced lung cancers.

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Nov. 9, 2018- Nov. 9, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 09, 2018

    Approved Credit:
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™

  • MORE INFOMORE INFO Immune Checkpoint Inhibitors in Lung Cancer: No Longer The Road Less Traveled?
    Collapse Introduction to Immunology – <i>Second Edition</i>

     

    Access the updated course, Introduction to Immunology – Third Edition

    Introduction to Immunology – Third Edition is a CME-, CPE-, CNE- and MOC-certified activity.

     

    Please note that continuing education credit for Introduction to Immunology – Second Edition is only available through October 9, 2019.

     

    Course Description

    This interactive course provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy. 

    intro_to_immunology_second_edition_screenshot_2.png

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.


    Faculty
    Christian M. Capitini, MD
    Assistant Professor
    University of Wisconsin Carbone Cancer Center


     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the function of the components of the immune system, including relevant cells, molecules and organs of the immune system.
    • Differentiate between the adaptive immune system and the innate immune system.
    • Recognize the barriers to effective immunotherapy, including mechanisms by which tumors locally disable and/or evade the immune system. 

     


    SITC Resources

    Due to the rapidly-evolving field of cancer immunotherapy, some of the content in this course may be out of date. For current information from SITC on cancer immunotherapy, please reference the following resources:

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     


    Continuing Education Information

     

    Credit Available: September 28, 2018- October 9, 2019

     

    Estimated time to complete activity: 1 hour

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-18-449-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.  Designated for 0.5 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Christian Capitini, MD: Consulting Fees at Nektar Therapeutics

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period September 28, 2018 through October 9, 2019 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Introduction to Immunology – Second Edition.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete the posttest with a passing score of 75% or better and the activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: September 28, 2018

    Approved Credit:
  • ACPE: 1 hour CEU
  • ANCC: 1 hour Contact Hour
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO Introduction to Immunology – <i>Second Edition</i>
    Collapse Optimizing Outcomes: Multidisciplinary Management of Advanced Bladder Cancer

    Access Course

     

    902370.jpg?interpolation=lanczos-none&resize=300:*Drs Milowsky and Smith discuss the evolving use of checkpoint inhibition in patients with advanced bladder cancer.

     

    This activity is intended for oncologists, urologists, nurses, and other healthcare professionals who treat patients with bladder cancer.

     

    The goal of this activity is to discuss the most up-to-date use of immunotherapy in the treatment of patients with advanced bladder cancer.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Sep. 27, 2018- Sep. 27, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 27, 2018

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™

  • MORE INFOMORE INFO Optimizing Outcomes: Multidisciplinary Management of Advanced Bladder Cancer
    Collapse The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer

    Access Course

     

    902337.jpg?interpolation=lanczos-none&resize=300:*Learn about current and emerging immunotherapy options and how to monitor for and manage immune-related adverse events.


    This activity is intended for nurses and nurse practitioners.

     

    The goal of this activity is to provide perspective on where immune checkpoint inhibitors fit into treatment paradigms, as well as on monitoring and management strategies for immune-related adverse events (irAEs).

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Sep. 26, 2018- Sep. 26, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 26, 2018

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour
  • ABIM: 1 hour CEU

  • MORE INFOMORE INFO The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer
    Collapse Novel Concepts in the Management of RCC

    Access Course

     

    900287.jpg?interpolation=lanczos-none&resize=300:*Drs Rini and McDermott discuss the latest approvals and ongoing research into immunotherapy for advanced RCC.
     

    This activity is intended for oncologists, urologists, and other healthcare professionals who treat patients with RCC.

     

    The goal of this activity is to discuss the evolving role of cancer immunotherapy in renal cell carcinoma (RCC).

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Sep. 19, 2018- Sep. 19, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 19, 2018
    MORE INFOMORE INFO Novel Concepts in the Management of RCC
    Collapse SITC 2017 Microlearning: Acquired Resistance Series

    SITC_Friday_2017_Khaaliq_Thomas-21.jpgThe SITC 2017 Microlearning: Acquired Resistance Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field. 


    The Acquired Resistance Series contains three modules. 

     

     

    Module 1: Acquired Resistance Checkpoint Inhibitors in Lung Cancer

    Katerina Politi, PhD - Yale School of Medicine


    Module 2: Acquired Resistance to PD-1 Blockade in Melanoma

    Antoni Ribas, MD, PhD - University of California, Los Angeles


    Module 3: Acquired Resistance in Melanoma

    Annette Paschen, MD - University Hospital Essen

     

    Target Audience

    These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

     

    Course Available Beginning: August 16, 2018

     

     

    Original Course Date: August 16, 2018
    MORE INFOMORE INFO SITC 2017 Microlearning: Acquired Resistance Series
    Collapse SITC 2017 Microlearning: Additional Topics Series

    Khaaliq_Thomas_SITC_2017_HS-8.jpgThe SITC 2017 Microlearning: Additional Topics Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field. 


    The SITC 2017 Microlearning: Additional Topics series contains three modules.

     

     

    Module 1: Genetically Modified T Cells for Solid Tumors

    Stephen Gottschalk, MD - St. Jude Children's Research Hospital


    Module 2: Improvement in Epitope Discovery

    Catherine J. Wu, MD - Dana-Farber Cancer Institute


    Module 3: Identification of Unique Neoantigen Qualities in Long-Term Pancreatic Cancer Survivors

    Vinod Balachandran, MD - Memorial Sloan Kettering Cancer Center

     

    Target Audience

    These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

     

    Course Available Beginning: August 16, 2018

     

     

    Original Course Date: August 16, 2018
    MORE INFOMORE INFO SITC 2017 Microlearning: Additional Topics Series
    Collapse SITC 2017 Microlearning: Clinical Trials - Novel Combinations Series

    SITC_Friday_2017_Khaaliq_Thomas-21.jpgThe SITC 2017 Microlearning Clinical Trials - Novel Combinations Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.
     

    The Clinical Trials - Novel Combinations series has three modules.

     

     

    Module 1: Early FDG-PET Response Correlates with Dose and Efficacy in Patients with Microsatellite Stable mCRC Treated with Carcinoembryonic Antigen T-cell Bispecific (CEA-TCB) Antibody Plus Atezolizumab

    Jose Saro, MD - Roche Innovation Center Zurich


    Module 2: First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti–CSF-1 Receptor (Cabiralizumab) Plus Anti–PD-1 (Nivolumab), in Patients with Advanced Solid Tumors

    Zev Wainberg, MD - UCLA School of Medicine


    Module 3: DNA Vaccine with PD-1 Blockade Elicits Anti-Tumor Responses in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC)

    Douglas McNeel, MD, PhD - University of Wisconsin

     

     

    Target Audience

    These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

     

    Course Available Beginning: August 16, 2018

     

     

    Original Course Date: August 16, 2018
    MORE INFOMORE INFO SITC 2017 Microlearning: Clinical Trials - Novel Combinations Series
    Collapse SITC 2017 Microlearning: Toxicities Series

    SITC_Friday_2017_Khaaliq_Thomas-21.jpgThe SITC 2017 Microlearning: Toxicities Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.  


    The Toxicities series contains three modules.

     

     

    Module 1: Antibody-Mediated Neutralization of Soluble MIC Significantly Enhances Response to CTLA4 Blockade and Reduces Therapy-Induced Colitis

    Jennifer Wu, PhD - Northwestern University


    Module 2: Pharmacological Management of irAEs

    Nathan Dahl, PharmD, R.Ph, BCOP - Clovis Oncology


    Module 3: Variance from Evidence-Based Management of Immune-Related Adverse Events Among Healthcare Providers: Analysis of an Online Management Decision Tool

    Krista Marcello, BA - Clinical Care Options, LLC

     

     

    Target Audience

    These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

     

    Course Available Beginning: August 16, 2018

     

     

    Original Course Date: August 16, 2018
    MORE INFOMORE INFO SITC 2017 Microlearning: Toxicities Series
    Collapse SITC 2017 Microlearning: Clinical Trials - New Agents Series

    SITC_Friday_2017_Khaaliq_Thomas-21.jpgThe SITC 2017 Microlearning: Clinical Trials - New Agents Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.  


    The Clinical Trials - New Agents series contains four modules. 

     

     

    Module 1: First-in-Human Study With Intratumoral Administration of a CD40 Agonistic Antibody: Preliminary Results With ADC-1013/JNJ-64457107 in Advanced Solid Malignancies

    Peter Ellmark, PhD - Alligator Bioscience


    Module 2: Initial Results from Phase 1 Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with NSCLC Refractory or Resistant to Prior Anti–PD-1/Anti–PD-L1 Agents

    James L. Gulley, MD, PhD, FACP - National Cancer Institute


    Module 3: A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients (pts) with Advanced Solid Tumors

    Glen J. Weiss, MD - Western Regional Medical Center Inc.


    Module 4: A Dual and Opposing Role for Tumor Intrinsic Type-II Interferon Sensing in Tumor Establishment and Acquired Resistance

    Jason Williams, BS - University of Chicago

     

     

    Target Audience

    These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

     

    Course Available Beginning: August 16, 2018

     

     

    Original Course Date: August 16, 2018
    MORE INFOMORE INFO SITC 2017 Microlearning: Clinical Trials - New Agents Series
    Collapse Introduction to Cancer Immunotherapy and the Immune System

    Access the updated patient course, 2019 Patient Course: Understanding Cancer Immunotherapy – Fifth Edition

     

    This activity is based on the Patient Resource Guide, Understanding Cancer Immunotherapy 4th Edition (published in December 2017), designed for newly diagnosed and restaged cancer patients and their caregivers. This interactive activity takes a closer look at how the immune system works to fight against cancer, cancer immunotherapy treatment types and clinical trials.

    d615c873-290c-4553-bd5d-bcb549ff6cb7.jpg

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

     

    Available beginning: May 22, 2018

     

    Approximate Time to Complete: 30 minutes

     

     

     

    This online patient education activity was produced with generous support from:

    35d50fdb-789b-42f6-8759-5ae752b880bc.jpg  
                      
                       

     

     

     

     

    Original Course Date: May 22, 2018
    MORE INFOMORE INFO Introduction to Cancer Immunotherapy and the Immune System
    Collapse Emerging Considerations in the Use of Immune Checkpoint Inhibitors: HCC

    Access Course

     

    892102.jpg?interpolation=lanczos-none&resize=300:*Drs Greten and El-Khoueiry discuss the emergence of checkpoint inhibition therapy in the treatment of advanced HCC.

     

    This activity is intended for oncologists, gastroenterologists, surgeons, and nurses.
     

    The goal of this activity is to review the latest data on the efficacy and safety of immune checkpoint inhibitors in the management of patients with advanced hepatocellular carcinoma (HCC).

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Mar. 09, 2018 - Mar. 09, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: March 09, 2018

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)™
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO Emerging Considerations in the Use of Immune Checkpoint Inhibitors: HCC
    Collapse Checkpoint Inhibitors: Managing Immune-Mediated Side Effects

    Access Course

     

    890963.jpg?interpolation=lanczos-none&resize=300:*Follow the cases of 2 patients who developed immune-related adverse events following treatment with immune checkpoint blockade.

     

    This activity is intended for oncologists, emergency medicine physicians, pulmonologists, and nurses.

     

    The goal of this activity is to review strategies for identifying and managing adverse events associated with treatment with immune checkpoint blockade.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Feb. 28, 2018 - Feb. 28, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 28, 2018

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)™
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO Checkpoint Inhibitors: Managing Immune-Mediated Side Effects
    Collapse The Evolving Role of Immunotherapy in NSCLC: Pearls for Clinical Practice

    Access Course

     

    890347.jpg?interpolation=lanczos-none&resize=300:*Faculty discuss recent and ongoing clinical trials that affect clinical decisions with the use of immunotherapy in NSCLC.


    This activity is intended for hematology/oncology specialists and pharmacists.
     

    The goal of this activity is to improve knowledge of clinical trial designs and practical application of data in order to improve management of patients with non-small cell lung cancer (NSCLC).

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Feb. 27, 2018 - Feb. 27, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 27, 2018

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACPE: 0.50 hours CEU
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO The Evolving Role of Immunotherapy in NSCLC: Pearls for Clinical Practice
    Collapse Treating Your Head and Neck Cancer: You

    Access Course

     

    889824-img1.pngThis article is for people who have advanced head and neck cancer and want to learn about working with their care team to share information about treatment and side effects and get support.

     

     

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Feb. 8, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 08, 2018
    MORE INFOMORE INFO Treating Your Head and Neck Cancer: You
    Collapse From Adjuvant to Metastatic in Melanoma: What Should You Know?

    Access Course

     

    From Adjuvant to Metastatic in Melanoma: What Should You Know?Experts discuss the role of immunotherapy in the treatment of patients with melanoma across the disease settings.

     

    This activity is intended for oncologists, dermatologists, pathologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.

     

    The goal of this activity is to discuss the evolving role for immunotherapy in the treatment of patients with melanoma.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 24, 2018 - Dec. 24, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 17, 2017

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)™
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour
  • ACPE: 0.50 hours CEU

  • MORE INFOMORE INFO From Adjuvant to Metastatic in Melanoma: What Should You Know?
    2017 Courses
    2016 Courses
    Collapse Determining the Best Treatment Algorithm for Patients with Head and Neck Cancer

    Access Course

     

    1a2ba882-5629-4b61-b437-e21681e56155.jpgExperts discuss treatment strategies for one patient with recurrent HNSCC and one with locally advanced HNSCC.

    This activity is intended for oncologists, pathologists, radiologists, surgeons, and other healthcare professionals who manage patients with head and neck cancer.
     

    The goal of this activity is to discuss the emergence of immunotherapy in head and neck cancer along with treatment approaches with both curative and noncurative disease and clinical trials.

     

    Approximate Time to Complete: 35 minutes

     

    Course Available Beginning: Dec. 20, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 20, 2016
    MORE INFOMORE INFO Determining the Best Treatment Algorithm for Patients with Head and Neck Cancer
    Collapse Kidney Cancer Treatments: Is One Option Better Than Another for Me?

    Access Course

     

    888494-fig1.pngThis article is for people who’ve had treatment for kidney cancer that has now spread, called metastatic renal cell carcinoma (mRCC). It’s also for their care partners and others who want to learn more about the next treatment choices. The goal is to learn about all your treatment options so you can better decide with your care team what’s right for you.

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Dec. 16, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 16, 2016
    MORE INFOMORE INFO Kidney Cancer Treatments: Is One Option Better Than Another for Me?
    Collapse Strengthening Lung Cancer Team Connections to Improve Outcomes with Immunotherapy

    Access Course

     

    dfaefd9d-8055-439e-8817-610fae557ffb.jpgWatch as an oncologist, pharmacist, and nurse discuss challenges and best practices for working in a team environment.

     


    This activity is intended for hematology and oncology specialists, nurses, advanced practice nurses and pharmacists.The goal of this activity is to identify interprofessional barriers and outline care team plans to achieve optimal outcomes for patients with non-small cell lung cancer (NSCLC).

     

     

    Approximate Time to Complete: 35 minutes

     

    Course Available Beginning: Dec. 16, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 16, 2016
    MORE INFOMORE INFO Strengthening Lung Cancer Team Connections to Improve Outcomes with Immunotherapy
    Collapse Clinical Challenges in Melanoma: Progressive Disease

    Access Course

     

    Clinical Challenges in Melanoma: Progressive DiseaseImaging scans suggest this patient's melanoma has progressed, but has it? Watch this case to see how it develops.

    This activity is intended for oncologists, dermatologists and pathologists.

    The goal of this activity is to review the treatment options and patterns of progression in patients being treated for metastatic melanoma.

     

     

     

    Approximate Time to Complete: 20 minutes

     

    Course Available Beginning: Dec. 7, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 07, 2016
    MORE INFOMORE INFO Clinical Challenges in Melanoma: Progressive Disease
    Collapse New Frontiers in Decision Making: Immunotherapy in Advanced Non-Squamous NSCLC

    Access Course

     

    medscapeact142016.JPGFollow a patient with advanced adenocarcinoma to learn about the use and management of immune checkpoint inhibitors.

    This activity is intended for hematology and oncology specialists, pulmonologists, and pathologists.


    The goal of this activity is to provide a review of the role of immunotherapy in the treatment of non-small cell lung cancer (NSCLC) and guidance for effective and safe integration into clinical practice.

     

     

    Approximate Time to Complete: 20 minutes

     

    Credit Available: Dec. 6, 2016- Dec. 6, 2017

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 06, 2016
    MORE INFOMORE INFO New Frontiers in Decision Making: Immunotherapy in Advanced Non-Squamous NSCLC
    Collapse New Frontiers in Decision Making: Adverse Events with Immunotherapy in NSCLC

    Access Course

     

    New Frontiers in Decision Making: Adverse Events With Immunotherapy in NSCLC

    Use a patient case to learn about managing adverse events with immunotherapy in patients with NSCLC.


    This activity is intended for hematology and oncology specialists, pulmonologists, and pathologists. 
     

    The goal of this activity is to address how to start integrating immune checkpoint inhibitors into lung cancer treatment.

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Dec. 6, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 06, 2016
    MORE INFOMORE INFO New Frontiers in Decision Making: Adverse Events with Immunotherapy in NSCLC
    Collapse Advancing the Care in Thoracic Cancer: Emerging Treatment Options

    Access Course

     

    9fcc4845-b7a8-4518-b7c8-171470014791.jpgRead three articles that review immunotherapy treatment options in mesothelioma, small cell lung cancer, and non-small cell lung cancer.


    This activity is intended for hematology/oncology specialists, pulmonologists, and pathologists.

    The goal of this activity is to increase awareness of immunotherapy as a treatment option for extensive disease in thoracic cancers.

     

     

    Approximate Time to Complete: 1 hour

     

    Course Available Beginning: Nov. 30, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 30, 2016
    MORE INFOMORE INFO Advancing the Care in Thoracic Cancer: Emerging Treatment Options
    Collapse Optimizing Outcomes in Metatastic Melanoma: A Case Challenge

    Access Course

     

    Medscape_act_21_2017.jpgReview appropriate treatment regimens for patients with metastatic melanoma.


    This educational activity is intended for clinicians practicing in the areas of hematology-oncology, dermatology, pathology and lab medicine. 


    The goal of this activity is to build healthcare professionals' confidence in strategies for the individualized treatment of the patient with malignant melanoma and to ensure that updated guidelines and other emerging best practices are applied across a variety of clinical presentations.

     

    Approximate Time to Complete: 1 hour

     

    Course Available Beginning: Nov. 22, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 22, 2016
    MORE INFOMORE INFO Optimizing Outcomes in Metatastic Melanoma: A Case Challenge
    Collapse Essential Concepts in Harnessing the Immune System in Head and Neck Cancer

    Access Course

     

    medscapeact122016.jpgDr. Tanguy Seiwert explores the emerging role for immunotherapy in head and neck cancer. 


    This activity is intended for oncologists, surgeons, and pathologists. 

    The goal of this activity is to discuss advances in the understanding of the role of the immune system in the head and neck cancer and strategies for using the immune system to treat head and neck cancer.

     

     

    Approximate Time to Complete: 40 minutes

     

    Course Available Beginning: Nov. 15, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 15, 2016
    MORE INFOMORE INFO Essential Concepts in Harnessing the Immune System in Head and Neck Cancer
    Collapse Immunotherapy Side Effects: Talking with Your Melanoma Care Team

    Access Course

     

    patient_medscape-melanoma_side_effects.jpgThis article is for people who are taking checkpoint inhibitor medicines for metastatic melanoma, their care partners, and others who want to learn about treatment side effects.

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Nov. 8, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 08, 2016
    MORE INFOMORE INFO Immunotherapy Side Effects: Talking with Your Melanoma Care Team
    Collapse Is Immunotherapy Right for My Lung Cancer?

    Access Course

     

    medscape-_LungPatient2.jpgThis activity is for people with non-small cell lung cancer who want to learn more about why, how, and when their care team may consider using immunotherapy as part of their treatment.

     

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Nov. 8, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 08, 2016
    MORE INFOMORE INFO Is Immunotherapy Right for My Lung Cancer?
    Collapse Clinical Challenges in Melanoma: Frontline

    Access Course

     

    617d9a96-bcfa-4ed5-8d8a-325b95a8c380.jpgA patient undergoing treatment for metastatic melanoma experiences some unusual symptoms. Watch this case to figure out what is going on.

    This activity is intended for oncologists, dermatologists, and pathologists.

    The goal of this activity is to review the treatment options and risks for immune-related adverse effects in patients being treated for metastatic melanoma.

     

     

     

    Approximate Time to Complete: 20 minutes

     

    Course Available Beginning: Oct. 21, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: October 21, 2016
    MORE INFOMORE INFO Clinical Challenges in Melanoma: Frontline
    Collapse New Frontiers in Decision Making: Immunotherapy in Advanced Squamous Cell NSCLC

    Access Course

     

    53fbb258-d3ff-479d-922a-3d8130eabc61.jpgFollow a patient with advanced squamous cell NSCLC to learn about the use and management of immune checkpoint inhibitors.


    This activity is intended for hematology and oncology specialists, pulmonologists, and pathologists.


    The goal of this activity is to provide a review of the role of immunotherapy in the treatment of non-small cell lung cancer (NSCLC) and guidance for effective and safe integration into clinical practice.

     

     

    Approximate Time to Complete: 20 minutes

     

    Course Available Beginning: Oct. 21, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: October 21, 2016
    MORE INFOMORE INFO New Frontiers in Decision Making: Immunotherapy in Advanced Squamous Cell NSCLC
    Collapse Is Immunotherapy for Lung Cancer the Same Thing as Chemotherapy?

    Access Course

     

    patient_medscape-_immunotherapy_the_same_as_chemo.jpgThis activity is for people with non-small cell lung cancer (NSCLC) who want to learn more about how immunotherapy differs from chemotherapy.

     

     

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Oct. 20, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: October 20, 2016
    MORE INFOMORE INFO Is Immunotherapy for Lung Cancer the Same Thing as Chemotherapy?
    Collapse What Treatment is Right for My Metatastic Melanoma

    Access Course

     

    patient_medscape-_melanoma.jpg

     

    This article is for people who have metastatic melanoma, their care partners, and others who want to learn about immunotherapy. This activity is intended for oncologists, dermatologists, pathologists, and healthcare practitioners who care for patients with metastatic melanoma. The goal of this activity is to educate clinicians in the practical application of recently approved systemic.

     

    Upon completion of this activity, participants will be able to:

    Select opitmal therapy for patients with metastatic melanoma that harbors v600 BRAF mutations and for patients with wild-type BRAF. Explain the role of immunotherapy in patients with V600 BRAF mutation-positive metastatic melanoma. Outline a sequential treatment strategy for patients with V600 BRAF mutation-positive metastatic melanoma. Describe how to manage side effects and assess response to immunotherapy and targeted therapy in patients being treated for metastatic melanoma. 

     

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Oct. 19, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: October 19, 2016
    MORE INFOMORE INFO What Treatment is Right for My Metatastic Melanoma
    Collapse Patient-Centered Management in Metastatic Renal Cell Carcinoma

    Access Course

     

    e3b71881-082a-4b52-b05c-867a9c5798ce.jpgExplore some of the main issues in the treatment of advanced RCC through two cases. 

     

    This activity is intended for oncologists, nephrologists, urologists, and other healthcare professionals who treat patients with advanced RCC.

     

    The goal of this activity is to examine the options for second-line treatment of mRCC as well as strategies for working with the patient.

     

     

    Approximate Time to Complete: 1 hour

     

    Course Available Beginning: Sep. 21, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 21, 2016
    MORE INFOMORE INFO Patient-Centered Management in Metastatic Renal Cell Carcinoma
    Collapse Priming T-Cells: Do We Understand the Strategies?

    Access Course

     

    0bd87a52-42d9-41ee-8176-461723604db4.jpgThree articles examine the role of T cells in the anticancer immune response and how they are being used in therapy.


    This activity is intended for hematologists and oncologists, pulmonologists and dermatologists.The goal of this activity is to explore advances being made in the harnessing of T cells for cancer immunotherapies.

     

     

    Approximate Time to Complete: 1.25 hours

     

    Credit Available: Sept. 15, 2016- Sept. 15, 2017

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 15, 2016
    MORE INFOMORE INFO Priming T-Cells: Do We Understand the Strategies?
    Collapse Spotlight on Immuno-Oncology in Melanoma

    Access Course

     

    966d4d06-8467-4d53-97ef-f5df8727a722.jpgDrs. Weber, Luke, and Gangadhar discuss the latest updates to existing immunotherapies and examine where the future may lie. 

    This activity is intended for hematologists, oncologists, dermatologists, and pathologists. 

    The goal of this activity is to review the latest advances in immunotherapy for melanoma.

     

     

    Approximate Time to Complete: 35 minutes

     

    Course Available Beginning: Aug. 31, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png

     

    Original Course Date: August 31, 2016
    MORE INFOMORE INFO Spotlight on Immuno-Oncology in Melanoma
    Collapse Pulmonologist Perspectives: The Use of Immune Checkpoint Inhibitors in Practice

    Access Course

     

    4a9408df-ed81-42bf-8167-018443e9f780.jpgLearn how treatment of NSCLC with checkpoint inhibitors will affect your clinical outlook.


    This activity is intended for pulmonologists, ID/HIV specialists, and pathologists who treat patients with lung cancer.

    The goal of this activity is to provide pulmonologists perspectives on how immune checkpoint inhibitors may alter the diagnostic algorithm in individuals with suspected lung cancer. 

     

     

    Approximate Time to Complete: 20 minutes

     

    Course Available Beginning: Aug. 31, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: August 31, 2016
    MORE INFOMORE INFO Pulmonologist Perspectives: The Use of Immune Checkpoint Inhibitors in Practice
    Collapse Emerging Considerations in the Use of Immune Checkpoints in Lung Cancer

    Access Course

     

    medscape5_v1.jpgDrs. Weiss, Borghaei, and Patel discuss the clinical data and practical implications for using checkpoint inhibitors to treat lung cancer. 


    This activity is intended for hematology and oncology specialists, pulmonologists and pathologists.
     

    The goal of this activity is to provide insight on how recently published clinical trials on immune checkpoint inhibitors should be incorporated into practice.

     

     

    Approximate Time to Complete: 40 minutes

     

    Course Available Beginning: Aug. 24, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: August 24, 2016
    MORE INFOMORE INFO Emerging Considerations in the Use of Immune Checkpoints in Lung Cancer
    Collapse Hiding in Plain Sight: How Cancer Evades the Immune System

    Access Course

     

    medscapeact22016.jpgDr. Robert Ferris reviews the working of the immune system and the development of cancer. 

    This activity is intended for hematologists, oncologists, pulmonologists, dermatologist, immunologists, primary care providers, and other healthcare providers who use cancer immunotherapies.

     

    The goal of this activity is to review the latest understanding of the relationship between the immune system and the tumor microenvironment as well as new immunotherapies in the management of patients with cancer. 

     

     

    Approximate Time to Complete: 30 minutes

     

    Course Available Beginning: Aug. 24, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: August 24, 2016
    MORE INFOMORE INFO Hiding in Plain Sight: How Cancer Evades the Immune System
    Collapse Cancer Immunotherapy: Pathways and Mechanisms of Actions

    Access Course

     

    4f67197e-85c7-4982-9169-585f0d5cb12b.jpg

    Experts discuss the basics of the immune system as well as existing and novel targets for cancer immunotherapy.

     

    This activity is intended for hematologist/oncologists, pulmonologists, dermatologists, and other healthcare professionals who use cancer immunotherapies.

     

    The goal of this activity is to review the role of the immune system in the development of tumors and research into the use of the immune system to fight tumors.

     

     

    Approximate Time to Complete: 1 hour

     

    Course Available Beginning: Aug. 24, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: August 24, 2016
    MORE INFOMORE INFO Cancer Immunotherapy: Pathways and Mechanisms of Actions
    Collapse Changing the Paradigm of Treatment in Patients with Hodgkin Lymphoma

    Access Course

     

    b827ba58-216e-4f06-897a-9cc44942e390.jpgDr. Stephen Ansell discusses the emerging role of immunotherapy in the management of patients with Hodgkin lymphoma.


    This activity is intended for hematologists, oncologists, pathologists, and other healthcare professionals who treat patients with Hodgkins lymphoma.


    The goal of this activity is to discuss the latest understanding of the role of the immune system in the development of Hodgkin lymphoma as well as strategies for harnessing the immune 

     

    Approximate Time to Complete: 30 minutes

     

    Course Available Beginning: Aug. 14, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: August 14, 2016
    MORE INFOMORE INFO Changing the Paradigm of Treatment in Patients with Hodgkin Lymphoma